Publications

Journals

• Johnson T; Gaunt TR; Newhouse SJ; Padmanabhan S; Tomaszewski M; Kumari M; Morris RW; Tzoulaki I; et alO'Brien ET; Poulter NR; Sever PSEA. (2011). Blood pressure loci identified with a gene-centric array. American Journal of Human Genetics. 89:1-13.
• Cholesterol Treatment Trialists' Collaboration. (2012). Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. PLoS One. 2012;7(1):e29849. Epub 2012 Jan 19..
• Beckett N; Peters R; Tuomilehto J; Swift C; Sever PS; Potter J; McCormack T; Forette F; et alGil-Extremera B; Dumitrascu D; Staessen JA; Thijs L; Fletcher A; Bulpitt C. (2012). Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ: British Medical Journal. 344:BMJ. 2011 Jan 4;344:d7541. doi: 10.1136/bmj.d7541.
• Gupta AK; Chang CL; Dahlof B; Poulter NR; Sever PS. (1 Oct 2011). Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up. JOURNAL OF HUMAN HYPERTENSION. 25:633-634.
• Gupta AK; Nasothimiou EG; Chang CL; Sever PS; Dahlöf B; Poulter NR; ASCOT investigators. (Oct 2011). Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens. 29:2004-2013. DOI.
• Sever PS; Chang CL; Gupta AK; Whitehouse A; Poulter NR; ASCOT Investigators. (Oct 2011). The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J. 32:2525-2532. DOI.
• Sever PS; Poulter NR; Chang CL; Hingorani A; Thom SA; Hughes AD; Welsh P; Sattar N; et alASCOT Investigators. (Feb 2012). Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 33:486-494. DOI.
• Gupta AK; Prieto-Merino D; Dahlöf B; Sever PS; Poulter NR; ASCOT Investigators. (Aug 2011). Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach. Diabet Med. 28:941-947. DOI.
• Chapman N; Chang CL; Caulfield M; Dahlöf B; Feder G; Sever PS; Poulter NR. (2011). Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Ethn Dis. 21:150-157.
• Sever PS; Messerli FH. (Oct 2011). Hypertension management 2011: optimal combination therapy. Eur Heart J. 32:2499-2506. DOI.
• Collier DJ; Poulter NR; Dahlöf B; Sever PS; Wedel H; Buch J; Caulfield MJ; ASCOT Investigators. (Mar 2011). Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. J Hypertens. 29:592-599. DOI.
• Collier DJ; Poulter NR; Dahlöf B; Sever PS; Wedel H; Buch J; Caulfield MJ; ASCOT Investigators. (Mar 2011). Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens. 29:583-591. DOI.
• Bunker J; Callister W; Chang CL; Sever PS. (Feb 2011). How common is true resistant hypertension?. J Hum Hypertens. 25:137-140. DOI.
• Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; et alGluud C; Messerli FH. (Jan 2011). Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 12:65-82. DOI.
• Gupta AK; Poulter NR; Dobson J; Eldridge S; Cappuccio FP; Caulfield M; Collier D; Cruickshank JK; et alSever PS; Feder G; ASCOT. (Sep 2010). Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial. Am J Hypertens. 23:1023-1030. DOI.
• Lindgren P; Eriksson J; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; et alJonsson B. (1 Aug 2010). The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 64:1228-1234. Author weblink DOI.
• Gupta AK; Dahlof B; Sever PS; Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm Investigators. (Jul 2010). Metabolic syndrome, independent of its components, is a risk factor for stroke and death but not for coronary heart disease among hypertensive patients in the ASCOT-BPLA. Diabetes Care. 33:1647-1651. DOI.
• Tapp RJ; Sharp A; Stanton AV; O'Brien E; Chaturvedi N; Poulter NR; Sever PS; Thom SA; et alHughes AD; Mayet J; ASCOT Investigators. (27 Apr 2010). Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. J Am Coll Cardiol. 55:1875-1881. DOI.
• Rothwell PM; Howard SC; Dolan E; O'Brien E; Dobson JE; Dahlöf B; Sever PS; Poulter NR. (13 Mar 2010). Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 375:895-905. DOI.
• Rothwell PM; Howard SC; Dolan E; O'Brien E; Dobson JE; Dahlöf B; Poulter NR; Sever PS; et alASCOT-BPLA and MRC Trial Investigators. (May 2010). Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 9:469-480. DOI.
• Sever PS; BHS Working Party. (2010). Aspirin and primary prevention. BHS reaffirms its guidance. BMJ. 340:c1183.
• Sharp AS; Tapp RJ; Thom SA; Francis DP; Hughes AD; Stanton AV; Zambanini A; O'Brien E; et alChaturvedi N; Lyons S; Byrd S; Poulter NR; Sever PS; Mayet J; ASCOT Investigators. (Mar 2010). Tissue Doppler E/E' ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy. Eur Heart J. 31:747-752. DOI.
• Prieto-Merino D; Gupta AK; Dobson J; Chang CL; Mastorantonakis S; Sever PS; Dahlof B; Wedel H; et alPocock S; Poulter NR. (1 Oct 2009). ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practices developed using the ASCOT trial database. JOURNAL OF HUMAN HYPERTENSION. 23:695-695. Author weblink.
• Poulter NR; Dobson JE; Sever PS; Dahlof B; Wedel H; Campbell NRC. (22 Sep 2009). Baseline Heart Rate, Antihypertensive Treatment, and Prevention of Cardiovascular Outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 54:1154-1161. Author weblink DOI.
• Manisty C; Mayet J; Tapp RJ; Sever PS; Poulter N; McG Thom SA; Hughes AD; ASCOT Investigators. (Nov 2009). Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). Hypertension. 54:1009-1013. DOI.
• Clunn GF; Sever PS; Hughes AD. (18 Feb 2010). Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and calcium channel blockers. Int J Cardiol. 139:2-6. DOI.
• Sever PS; Gradman AH; Azizi M. (Jun 2009). Managing cardiovascular and renal risk: the potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst. 10:65-76. DOI.
• Sever PS; Poulter NR; Dahlof B; Wedel H. (1 May 2009). Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. JOURNAL OF HYPERTENSION. 27:947-954. Author weblink DOI.
• Sever PS; Poulter NR; Mastorantonakis S; Chang CL; Dahlof B; Wedel H; ASCOT Investigators. (26 Jun 2009). Coronary heart disease benefits from blood pressure and lipid-lowering. Int J Cardiol. 135:218-222. DOI.
• Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B; et alASCOT investigators. (2009). The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1. Pharmacoeconomics. 27:221-230.
• Ostergren J; Poulter NR; Sever PS; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; et alKjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E. (1 Nov 2008). The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. JOURNAL OF HYPERTENSION. 26:2103-2111. Author weblink DOI.
• Gupta AK; Poulter NR; Eldridge S; Cappuccio FP; Caulfield MJ; Dobson J; Cruickshank JK; Griffiths CJ; et alHemingway H; Sever PS; Feder G. (1 Oct 2008). Ethnic differences in blood pressure response to atenolol and amlodipine monotherapy and to add on diuretic and ACE inhibitor dual therapy in hypertensive patients from UK in ASCOT-BPLA. JOURNAL OF HUMAN HYPERTENSION. 22:726-727. Author weblink.
• Sharp A; Tapp R; Francis DP; McG Thom SA; Hughes AD; Stanton AV; Zambanini A; Chaturvedi N; et alByrd S; Poulter NR; Sever PS; Mayet J. (16 Sep 2008). Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. J Am Coll Cardiol. 52:1015-1021. DOI.
• Chapman N; Chang CL; Dahlof B; Sever PS; Wedel H; Poulter NR. (1 Jul 2008). Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. CIRCULATION. 118:42-48. Author weblink DOI.
• Gupta AK; Dahlof B; Dobson J; Sever PS; Wedel H; Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. (May 2008). Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 31:982-988. DOI.
• Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B; et alASCOT trial investigators. (Feb 2008). Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. Heart. 94:e4. DOI.
• Sever PS; Poulter NR; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; et alKristinsson A; McInnes G; Mehlsen J; Nieminen MS; O'Brien ET; Ostergren J. (1 Feb 2008). The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. EUROPEAN HEART JOURNAL. 29:499-508. Author weblink DOI.
• Chapman N; Dobson J; Wilson S; Dahlof B; Sever PS; Wedel H; Poulter NR. (1 Sep 2007). Spironolactone in resistant hypertension - Reply. HYPERTENSION. 50:E58-E58. Author weblink DOI.
• Chapman N; Dobson J; Wilson S; Dahlöf B; Sever PS; Wedel H; Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. (Apr 2007). Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 49:839-845. DOI.
• Sever P; Dahlöf B; Poulter N; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S; et alKristinsson A; McInnes G; Mehlsen J; Nieminem M; O'Brien E; Ostergren J; ASCOT Steering Committee Members. (Dec 2006). Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 27:2982-2988. DOI.
• Sever PS; Poulter NR. (13 Jun 2006). Blood pressure reduction is not the only determinant of outcome - Response to Elliott et al. CIRCULATION. 113:2773-2773. Author weblink.
• Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR; Sever PS; Poulter NR; Elliott WJ; et alJonsson MC; Black HR. (13 Jun 2006). Blood pressure reduction is not the only determinant of outcome. Circulation. 113:2754-2772. DOI.
• Sever PS; Poulter NR. (13 Jun 2006). Management of hypertension: is it the pressure or the drug? Blood pressure reduction is not the only determinant of outcome. CIRCULATION. 113:2754-2763. Author weblink DOI.
• Sever PS. (Dec 2005). Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?. AM J MED. 118:3S-9S.
• Poulter NR; Sever PS; Dahlof B; Wedel H. (1 Oct 2005). Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes - Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA) - Response to Tseng. DIABETES CARE. 28:2595-2596. Author weblink.
• Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; et alKristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; ASCOT Investigators. (10 Sep 2005). Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 366:895-906. DOI.
• Poulter NR; Wedel H; Dahlöf B; Sever PS; Beevers DG; Caulfield M; Kjeldsen SE; Kristinsson A; et alMcInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; Pocock S; ASCOT Investigators. (10 Sep 2005). Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 366:907-913. DOI.
• Sever PS; Poulter NR; Dahlöf B; Wedel H; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. (5 Sep 2005). Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol. 96:39F-44F. DOI.
• Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; et alKristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J. (May 2005). Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care. 28:1151-1157.
• Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B; et alASCOT investigators. (Feb 2005). Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil. 12:29-36.
• Williams B; Poulter NR; Brown MJ; Davis M; McInnes GT; Potter JF; Sever PS; Thom SM; et alBHS guidelines working party, for the British Hypertension Society. (13 Mar 2004). British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 328:634-640. DOI.
• Williams B; Poulter NR; Brown MJ; Davis M; McInnes GT; Potter JF; Sever PS; McG Thom S; et alBritish Hypertension Society. (Mar 2004). Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 18:139-185. DOI.
• Sever PS; Dahlof B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; et alKristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; ASCOT investigators. (Feb 2004). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid lowering arm (ASCOT-LLA): A multicentre randomised controlled trial. DRUGS. 64:43-60.
• Sever PS; Dahlof B; Poulter N; Wedel H. (7 Jun 2003). ASCOT-LLA: questions about the benefits of atorvastatin - Reply. LANCET. 361:1986-1987. Author weblink DOI.
• Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; et alKristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; ASCOT investigators. (5 Apr 2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 361:1149-1158. DOI.
• Jackson G; Betteridge J; Dean J; Eardley I; Hall R; Holdright D; Holmes S; Kirby M; et alRiley A; Sever P. (Nov 2002). A systematic approach to erectile dysfunction in the cardiovascular patient: a Consensus Statement--update 2002. Int J Clin Pract. 56:663-671.
• Ariff B; Stanton A; Barratt D; Augst A; Glor F; Poulter N; Sever P; Xu Y; et alHughes A; Thom SA. (Jun 2002). Comparison of the effects of antihypertensive treatment with angiotensin II blockade and beta-blockade on carotid wall structure and haemodynamics: protocol and baseline demographics. J Renin Angiotensin Aldosterone Syst. 3:116-122. DOI.
• Sever P. (Jun 2002). The SCOPE trial. Study on Cognition and Prognosis in the Elderly. J Renin Angiotensin Aldosterone Syst. 3:61-62. DOI.
• Clunn GF; Patel MK; Sever PS; Hughes AD. (1 Mar 2002). Inhibition of rho-kinase impairs chemotaxis and mitogenesis and induces a change in morphology in human vascular smooth muscle cells. BRITISH JOURNAL OF PHARMACOLOGY. 135. Author weblink.
• Sever P; Poulter N. (2002). Hypertension trials - the current evidence base and forthcoming trials. Br J Cardiol. 9:640-644.
• Stanton AV; Chapman JN; Mayet J; Sever PS; Poulter NR; Hughes AD; Thom SA. (Nov 2001). Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. Clin Sci (Lond). 101:455-464.
• Clunn GF; Patel MK; Sever PS; Hughes AD. (1 Oct 2001). Involvement of Rho-kinase in control of human vascular smooth muscle cell chemotaxis, mitogenesis and morphology. HYPERTENSION. 38:984-984. Author weblink.
• Garcha RS; Sever PS; Hughes AD. (Sep 2001). Mechanism of action of angiotensin II in human isolated subcutaneous resistance arteries. Br J Pharmacol. 134:188-196. DOI.
• Stanton A; Fitzgerald D; Hughes A; Mayet J; O'Brien E; Poulter NR; Sever PS; Shields D; et alThom S; Anglo-Scandinavian Cardiac Outcomes Trial. (Aug 2001). An intensive phenotyping study to enable the future examination of genetic influences on hypertension-associated cardiovascular disease. J Hum Hypertens. 15 Suppl 1:S13-S18.
• Sever PS; Dahlof B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; et alMcInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J. (1 Aug 2001). Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol. JOURNAL OF HUMAN HYPERTENSION. 15:S11-S12. Author weblink.
• Thom S; Whitehouse A; Sever P; Poulter N; Anglo-Scandinavian Cardiac Outcomes Trial. (Aug 2001). Non-specific effects of inclusion in a clinical trial: information from ASCOT. J Hum Hypertens. 15 Suppl 1:S81-S82.
• Sever PS; Hughes A. (Jun 2001). Angiotensin receptor antagonists and vaso-vagal attacks due to sensitisation of the Bezold-Jarisch reflex?. J Hum Hypertens. 15:437-438. DOI.
• Sever PS; Dahlof B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; et alMcInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J. (1 Jun 2001). Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial. JOURNAL OF HYPERTENSION. 19:1139-1147. Author weblink DOI.
• Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; et alMcInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J. (Jun 2001). Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens. 19:1139-1147.
• Sever PS; Chang CL. (Mar 2001). Discordant responses to two classes of drugs acting on the renin-angiotensin system. J Renin Angiotensin Aldosterone Syst. 2:25-30. DOI.
• Bulpitt C; Fletcher A; Beckett N; Coope J; Gil-Extremera B; Forette F; Nachev C; Potter J; et alSever P; Staessen J; Swift C; Tuomilehto J. (2001). Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging. 18:151-164.
• Sever PS. (Dec 2000). To block the renin system or the calcium channel in hypertension--where do we stand?. J Renin Angiotensin Aldosterone Syst. 1:325-327. DOI.
• Ibrahim J; Hughes AD; Sever PS. (Nov 2000). Action of angiotensin II on DNA synthesis by human saphenous vein in organ culture. Hypertension. 36:917-921.
• Mayet J; Ariff B; Wasan B; Chapman N; Shahi M; Poulter NR; Sever PS; Foale RA; et alThom SA. (Nov 2000). Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy. Hypertension. 36:755-759.
• McInnes GT; Mancia G; Sever PS; Poulter NR. (Oct 2000). Applying evidence-based medicine to current practice: a round table panel discussion. J HUM HYPERTENS. 14:S17-S22.
• Sever PS; Poulter NR. (Oct 2000). Hypertension drug trials: past, present, and future. J Hum Hypertens. 14:729-738.
• Garcha RS; Sever PS; Hughes AD. (1 Oct 2000). Mechanisms of angiotensin II-induced contraction in human isolated subcutaneous resistance arteries. HYPERTENSION. 36:672-672. Author weblink.
• Sever PS. (1 Oct 2000). The do's and don'ts when using AIIRAs in daily practice in hypertension: an introduction. JOURNAL OF HUMAN HYPERTENSION. 14:S1-S1. Author weblink DOI.
• Sever PS. (Aug 2000). Coronary heart disease prevention As the primary goal in contemporary trials in the treatment of hypertension. Curr Hypertens Rep. 2:418-420.
• Guzzetti S; Mayet J; Shahi M; Mezzetti S; Foale RA; Sever PS; Poulter NR; Porta A; et alMalliani A; Thom SA. (May 2000). Absence of sympathetic overactivity in Afro-Caribbean hypertensive subjects studied by heart rate variability. J Hum Hypertens. 14:337-342.
• Chalmers RT; Dhadwal A; Deal JE; Sever PS; Wolfe JH. (Apr 2000). The surgical management of renovascular hypertension in children and young adults. Eur J Vasc Endovasc Surg. 19:400-405. DOI.
• Hollenberg NK; Sever PS. (Mar 2000). The past, present and future of hypertension management: a potential role for AT(1)-receptor antagonists. J Renin Angiotensin Aldosterone Syst. 1:5-10. DOI.
• Chapman JN; French AT; Poulter NR; Sever PS. (Feb 2000). Page's syndrome: a case of pseudophaeochromocytoma. J Hum Hypertens. 14:149-150.
• Hollenberg NK; Sever PS. (1 Jan 2000). Candesartan cilexetil: From concept to clinic - Proceedings of an international meeting held in Lisbon, Portugal, October 1998 - Foreword. BLOOD PRESSURE. 9:4-4. Author weblink DOI.
• Sever PS. (Jan 2000). Improving antihypertensive efficacy while maintaining placebo-like tolerability. BLOOD PRESSURE. 9:19-22.
• Sever PS. (Nov 1999). Simple blood pressure guidelines for primary health care. J Hum Hypertens. 13:725-727.
• Garcha RS; Sever PS; Hughes AD. (Aug 1999). Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries. Br J Pharmacol. 127:1876-1882. DOI.
• Ibrahim J; Schachter M; Hughes AD; Sever PS. (Aug 1999). Low dose indapamide plus perindopril combination effects on cardiovascular structure and function in genetic hypertension. Clin Exp Pharmacol Physiol. 26:622-627.
• Sever PS. (Aug 1999). Recent clinical trials: a critical appraisal. Curr Hypertens Rep. 1:333-336.
• Sever PS; de Chatel R; Cifkova R; Sznajderman M; Notter T; Zilles P. (1 Apr 1999). Antihypertensive efficacy and safety of verapamil SR trandolapril (240/2 mg) in patients insufficiently pretreated with verapamil SR 240 mg monotherapy. AMERICAN JOURNAL OF HYPERTENSION. 12:135A-135A. Author weblink.
• Mayet J; Kanagaratnam P; Shahi M; Senior R; Doherty M; Poulter NR; Sever PS; Handler CE; et alThom SA; Foale RA. (Apr 1999). QT dispersion in athletic left ventricular hypertrophy. Am Heart J. 137:678-681.
• Sever PS; Oparil S. (1 Jan 1999). Unexplored territories with calcium channel blockers: Potential for the future - Official Satellite Symposium for the XVIIIth Congress of the European Society of Cardiology the National Exhibition Centre, Birmingham, United Kingdom August 28, 1994 - Introduction. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 33:V-VI. Author weblink DOI.
• Sever PS. (1999). Alpha 1-blockers in hypertension. Curr Med Res Opin. 15:95-103. DOI.
• Sever PS. (1 Jan 1999). Angiotensin II receptor antagonists: From science to clinical practice - Proceedings of a sponsored Symposium to the 17th Scientific Meeting of the International Society of Hypertension, Amsterdam, June 7-11, 1998 - Closing remarks. JOURNAL OF HUMAN HYPERTENSION. 13:S83-S83. Author weblink.
• Mallion JM; Unger T; Sever PS; Miyazaki M; Brenner BM; Ogihara T. (1 Jan 1999). Discussion 1 - New refinements in the approach to hypertension management. JOURNAL OF HUMAN HYPERTENSION. 13:S33-S34. Author weblink.
• Sever PS; Brenner BM; Unger T; Kurokawa K. (1 Jan 1999). Effects of candesartan on the proteinuria of chronic glomerulonephritis - Discussion 2 (part B). JOURNAL OF HUMAN HYPERTENSION. 13:S61-S61. Author weblink.
• Sever PS. (1 Jan 1999). Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. JOURNAL OF HUMAN HYPERTENSION. 13:S3-S10. Author weblink DOI.
• Brenner BM; Yamazaki T; Unger T; Sever PS; Mallion JM. (1 Jan 1999). Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress - Discussion 2 (part A). JOURNAL OF HUMAN HYPERTENSION. 13:S49-S50. Author weblink.
• Stanton AV; Chapman JN; Sever PS; Poulter NR; Hughes AD; Thom SA. (1 Oct 1998). Greater regression of early atherosclerosis by calcium channel blockade than by angiotensin converting enzyme inhibition. HYPERTENSION. 32:795-795. Author weblink.
• Refson JS; Schachter M; Patel MK; Hughes AD; Munro E; Chan P; Wolfe JH; Sever PS. (30 Jun 1998). Vein graft stenosis and the heparin responsiveness of human vascular smooth muscle cells. Circulation. 97:2506-2510.
• Garcha RS; Sever PS; Hughes AD. (1 Jun 1998). Angiotensin II contracts human resistance arteries via tyrosine kinase activation and calcium channel opening. JOURNAL OF HYPERTENSION. 16:S3-S3. Author weblink.
• Hughes AD; Clunn GF; Lymn JS; Sampson LJ; Patel MK; Sever PS. (1 Jun 1998). Differentiation state affects the ability of Ca2+ channel antagonists to inhibit migration in human vascular smooth muscle cells. JOURNAL OF HYPERTENSION. 16:S16-S16. Author weblink.
• Stanton AV; Chapman JN; Sever PS; Poulter NR; Hughes AD; Thom SA. (1 Jun 1998). Greater regression of early atherosclerosis by calcium channel blockade than by angiotensin converting enzyme inhibition. JOURNAL OF HYPERTENSION. 16:S25-S25. Author weblink.
• Dahlof B; Sever PS; Poulter NR; Wedel H. (1 Jun 1998). The Anglo-Scandinavian cardiac outcomes trial (ASCOT). JOURNAL OF HYPERTENSION. 16:S212-S212. Author weblink.
• Mayet J; Chapman N; Li CK; Shahi M; Poulter NR; Sever PS; Foale RA; Thom SA. (May 1998). Ethnic differences in the hypertensive heart and 24-hour blood pressure profile. Hypertension. 31:1190-1194.
• Garcha RS; Sever PS; Hughes AD. (20 Mar 1998). Action of losartan metabolite E-3174, tyrosine kinase inhibition and calcium channel blockade on angiotensin-II (AII) responses in human resistance arteries. FASEB JOURNAL. 12:A1002-A1002. Author weblink.
• Hughes AD; Garcha RS; Sever PS. (1 Jan 1998). Application of a two state model to the action of AT(1) antagonists in human resistance arteries. JOURNAL OF VASCULAR RESEARCH. 35:20-20. Author weblink.
• Garcha RS; Sever PS; Hughes AD. (1 Jan 1998). Role of Ca2+ channels, MAP/ERK kinase (MEK) in angiotensin II-induced contraction in human isolated resistance arteries. JOURNAL OF VASCULAR RESEARCH. 35:18-18. Author weblink.
• Sever PS. (Dec 1997). Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil. J Hypertens Suppl. 15:S9-12.
• Mayet J; Shahi M; Poulter NR; Sever PS; Foale RA; Thom SA. (Sep 1997). Left ventricular geometry in presenting untreated hypertension. J Hum Hypertens. 11:593-594.
• Mayet J; O'Kane KP; Elton R; Johnstone HA; Shahi M; Ozkor MA; Stanton AV; Poulter NR; et alSever PS; Foale RA; Webb DJ; Thom SA. (Sep 1997). Left ventricular hypertrophy, blood pressure and ACE genotype in untreated hypertension. J Hum Hypertens. 11:595-597.
• Sever PS. (1 Jul 1997). Blood pressure control for the hypertensive patient - What can we do better?. AMERICAN JOURNAL OF HYPERTENSION. 10:S128-S130. Author weblink DOI.
• Sever PS. (Jul 1997). Blood pressure control for the hypertensive patient: what can we do better?. Am J Hypertens. 10:128S-130S.
• Kaplan NM; Sever PS. (1 Jul 1997). Combination therapy: A key to comprehensive patient care. AMERICAN JOURNAL OF HYPERTENSION. 10:S127-S127. Author weblink DOI.
• Kaplan NM; Sever PS. (Jul 1997). Combination therapy: a key to comprehensive patient care. Am J Hypertens. 10:127S.
• Mayet J; Chapman N; Shahi M; Poulter NR; Cunningham DA; Dave S; Kooner J; Sever PS; et alFoale RA; Thom SA. (Jun 1997). The effects on cardiac arrhythmias of antihypertensive therapy causing regression of left ventricular hypertrophy. Am J Hypertens. 10:611-618.
• Mayet J; Shahi M; McGrath K; Poulter NR; Sever PS; Foale RA; Thom SA. (Nov 1996). Left ventricular hypertrophy and QT dispersion in hypertension. Hypertension. 28:791-796.
• Thom SA; Stanton AV; King LA; Sever PS; Hughes AD. (1 Oct 1996). Arteriolar length-diameter ratio; A geometric parameter of the retinal vasculature diagnostic of hypertension. HYPERTENSION. 28:703-703. Author weblink.
• Stanton AV; Mayet J; Hughes AD; Chapman NJ; Sever PS; Thom SA. (1 Oct 1996). Carotid and femoral artery intima-media thickness is similar in black and white hypertensive patients. HYPERTENSION. 28:703-703. Author weblink.
• Ibrahim J; Hughes AD; Sever PS. (1 Oct 1996). Non-AT1/AT2 receptor mediated growth by angiotensin II in human saphenous vein in culture. HYPERTENSION. 28:701-701. Author weblink.
• Mayet J; Shahi M; McGrath K; Poulter NR; Sever PS; Foale RA; Thom SA. (1 Oct 1996). QT dispersion is improved by antihypertensive therapy. HYPERTENSION. 28:703-703. Author weblink.
• Schachter M; Sawhney N; Refson JS; Hughes AD; Sever PS. (1 Oct 1996). Thrombospondin and growth regulation in human vascular smooth muscle cells. HYPERTENSION. 28:704-704.
• vanZwieten PA; Ambrosioni E; Sever PS; MacMahon S; Frohlich ED; Krakoff LR; Zanchetti A; Swales JD; et alHansson L; Mancia G; Menard J. (1 Sep 1996). Cost-effectiveness calculations from trials - Discussion. JOURNAL OF HYPERTENSION. 14:S52-S54. Author weblink.
• Sever PS; Luscher TF; vanZwieten PA; Salvetti A; Sleight P; AgabitiRosei E; Mancia G; Hamet P. (1 Sep 1996). Endothelial function as an end-point in interventional trials: Concepts, methods and current data - Discussion. JOURNAL OF HYPERTENSION. 14:S119-S121. Author weblink.
• Mancia G; MacMahon S; Zanchetti A; Sever PS; Lindholm L; Hansson L; Sleight P; AgabiteiRosei E; et alSalvetti A. (1 Sep 1996). Methodological aspects: General discussion. JOURNAL OF HYPERTENSION. 14:S27-S28. Author weblink.
• vanZwieten PA; Lindholm LH; Devereux RB; Zanchetti A; Menard J; Sever PS. (1 Sep 1996). Safety of the calcium antagonist lacidipine evaluated from a phase Ill-IV trial database - Discussion. JOURNAL OF HYPERTENSION. 14:S20-S20. Author weblink.
• Sever PS; Mackay JA. (Sep 1996). The hypertension trials. J HYPERTENS. 14:S29-S33.
• Frohlich ED; Sever PS; Hansson L; Menard J. (1 Sep 1996). The hypertension trials - Discussion. JOURNAL OF HYPERTENSION. 14:S33-S34. Author weblink.
• Frohlich ED; Rahn KH; Hansson L; Sever PS; AgabitiRosei E; Arakawa K; Lindholm L. (1 Sep 1996). The optimal blood pressure reduction - Discussion. JOURNAL OF HYPERTENSION. 14:S58-S59. Author weblink.
• Ibrahim J; Hughes AD; Schachter M; Sever PS. (Aug 1996). Depletion of resistance vessel polyamines attenuates angiotensin II induced blood pressure rise in rats. Clin Exp Hypertens. 18:811-830.
• Poulter NR; Zographos D; Mattin R; Sever PS; Thom SM. (Jul 1996). Concomitant risk factors in hypertensives: a survey of risk factors for cardiovascular disease amongst hypertensives in English general practices. Blood Press. 5:209-215.
• Pickkers P; Schachter M; Hughes AD; Feher MD; Sever PS. (Jul 1996). Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?. Diabetologia. 39:861-864.
• King LA; Stanton AV; Sever PS; Thom SA; Hughes AD. (Jun 1996). Arteriolar length-diameter (L:D) ratio: a geometric parameter of the retinal vasculature diagnostic of hypertension. J Hum Hypertens. 10:417-418.
• MacGregor GA; Sever PS. (18 May 1996). Salt - Overwhelming evidence but still no action: Can a consensus be reached with the food industry?. BRITISH MEDICAL JOURNAL. 312:1287-1289. Author weblink.
• MacGregor GA; Sever PS. (18 May 1996). Salt--overwhelming evidence but still no action: can a consensus be reached with the food industry? CASH (Consensus Action on Salt and Hypertension). BMJ. 312:1287-1289.
• Mackay JA; Sever PS. (May 1996). Calcium channel blockers in the dock: innocent or guilty?. J Hum Hypertens. 10:277-280.
• Ibrahim J; Hughes AD; Schachter M; Sever PS. (May 1996). Enhanced tissue polyamine content in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol. 23:410-414.
• Garcha RS; Schachter M; Sever PS; Hughes AD. (8 Mar 1996). Action of losartan, PD-123,319 and endothelial factors on angiotensin-II (AII) responses in human resistance arteries. FASEB JOURNAL. 10:4004-4004. Author weblink.
• Patel MK; Betteridge LJ; Hughes AD; Clunn GF; Schachter M; Shaw RJ; Sever PS. (Mar 1996). Effect of angiotension II on the expression of the early growth response gene c-fos and DNA synthesis in human vascular smooth muscle cells. J Hypertens. 14:341-347.
• Luccioni R; Sever PS; Di Perri T; Redon J; Laurandin I; Brault Y; Chastang C; Guez D. (Dec 1995). An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension. J Hypertens. 13:1847-1851.
• Pickkers P; Schachter M; Sever PS; Hughes AD. (Aug 1995). Do KCa channels and carbonic anhydrase play a role in thiazide-induced hyperglycaemia?. J Hum Hypertens. 9:691-693.
• Mayet J; Stanton AV; Sinclair AM; MacKay J; Shahi M; Foale RA; Nicolaides A; Poulter NR; et alSever PS; Thom SA. (Jul 1995). The effects of antihypertensive therapy on carotid vascular structure in man. Cardiovasc Res. 30:147-152.
• Mayet J; Shahi M; Poulter NR; Sever PS; Foale RA; Thom SA. (30 Jun 1995). Left ventricular diastolic function in hypertension: a 4 year follow-up study. Int J Cardiol. 50:181-188.
• Mayet J; Shahi M; Hughes AD; Stanton AV; Poulter NR; Sever PS; Foale RA; Thom SA. (Jun 1995). Left ventricular structure and function in previously untreated hypertensive patients: the importance of blood pressure, the nocturnal blood pressure dip and heart rate. J Cardiovasc Risk. 2:255-261.
• Patel MK; Chan P; Betteridge LJ; Schachter M; Sever PS. (Apr 1995). Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol. J Cardiovasc Pharmacol. 25:652-657.
• Mayet J; Shahi M; Poulter NR; Sever PS; Thom SA; Foale RA. (Feb 1995). Ventricular arrhythmias in hypertension: in which patients do they occur?. J Hypertens. 13:269-276.
• Ibrahim J; Schachter M; Hughes AD; Sever PS. (Jan 1995). Role of polyamines in hypertension induced by angiotensin II. Cardiovasc Res. 29:50-56.
• Hughes AD; Sinclair AM; Geroulakos G; Mayet J; Mackay J; Shahi M; Thom S; Nicolaides A; et alSever PS. (Jan 1995). Structural changes in the cardiovascular system of untreated essential hypertensives. Blood Press. 4:42-47.
• MAYET J; SHAHI M; THOM SAM; POULTER NR; SEVER PS. (1 Oct 1994). COMPLEX VENTRICULAR ARRHYTHMIAS OCCUR COMMONLY IN TREATED, BUT RARELY IN UNTREATED HYPERTENSIVES. CIRCULATION. 90:565-565. Author weblink.
• Calder JA; Schachter M; Sever PS. (Jul 1994). Potassium channel opening properties of thiazide diuretics in isolated guinea pig resistance arteries. J Cardiovasc Pharmacol. 24:158-164.
• SCHACHTER M; SEVER PS; CALDER JA. (1 May 1994). EFFECT OF THIAZIDE-LIKE DRUGS ON CALCIUM HOMEOSTASIS IN CULTURED GUINEA-PIG VASCULAR SMOOTH-MUSCLE CELLS. BRITISH JOURNAL OF PHARMACOLOGY. 112:U98-U98. Author weblink.
• CALDER JA; SCHACHTER M; SEVER PS. (1 May 1994). INDAPAMIDE BINDING IN GUINEA-PIG VASCULAR SMOOTH-MUSCLE CELLS. BRITISH JOURNAL OF PHARMACOLOGY. 112:U216-U216. Author weblink.
• Calder JA; Schachter M; Sever PS. (21 Apr 1994). Vasorelaxant actions of 5-OH-indapamide, a major metabolite of indapamide: comparison with indapamide, hydrochlorothiazide and cicletanine. Eur J Pharmacol. 256:185-191.
• Mayet J; Shahi M; Foale RA; Poulter NR; Sever PS; McG Thom SA. (16 Apr 1994). Racial differences in cardiac structure and function in essential hypertension. BMJ. 308:1011-1014.
• Sever PS. (Apr 1994). Management targets and thresholds for treatment. Br Med Bull. 50:460-471.
• CALDER JA; SCHACHTER M; SEVER PS. (1 Jan 1994). COMPARISON OF INDAPAMIDE, 5-OH INDAPAMIDE AND HYDROCHLOROTHIAZIDE IN ISOLATED SMALL VESSELS. BRITISH JOURNAL OF PHARMACOLOGY. 111:P247-P247. Author weblink.
• Sunman W; Sever PS. (Dec 1993). Non-angiotensin effects of angiotensin-converting enzyme inhibitors. Clin Sci (Lond). 85:661-670.
• BEHOUNEK BD; MARKOWITZ JS; BERGMAN M; MCGOVERN ME; KASSLERTAUB KB; VANHANEN H; ELORANTA M; JUVONEN J; et alKANTOLA I; KEKKI S; KIVELA H; KNUTAR F; NISSEN M; SALMI J; SALONEN R; TARPILA S; TUNTURIHIHNALA H; AMANN FW; BERENDES G; BONNER G; DUBACH UC; EGGSTEIN M; FRANKENBERG HV; FROER KL; HOHL H; HOPPE F; KUMMER H; MARZ W; MOCCETTI T; NOSEDA G; REUTTER FW; SCHWENKE R; VOSSCHULTE G; WAMBACH G; WEIDMANN P; BONNIER JJRM; DEWEERD P; HUIGE MC; JANSEN LJ; TERIJDT AJ; TEVELDE K; OLSSON AG; LARSSON H; ASPLUND J; DAHLQVIST A; LONNQVIST F; FRITHZ G; HOGLUND C; KJELLSTROM T; KUYLENSTIERNA J; MOLLER B; OSTERGREN J; CRAMB R; DAVIES J; IVERSON; JOHNSTON GD; MUNRO A; PEACOCK I; RITCHIE LD; RITTER J; RYLANCE PB; SEVER PS; SIMMONS RL. (1 Nov 1993). EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FROM 5.2 TO 7.8 MMOL LITER (200 TO 300 MG DL) PLUS 2 ADDITIONAL ATHEROSCLEROTIC RISK-FACTORS. AMERICAN JOURNAL OF CARDIOLOGY. 72:1031-1037. Author weblink.
• MAYET J; SHAHI M; THOM S; POULTER N; SEVER PS; FOALE RA. (1 Oct 1993). DOES DIASTOLIC FUNCTION IMPROVE AFTER PROLONGED REGRESSION OF HYPERTENSIVE LEFT-VENTRICULAR HYPERTROPHY. CIRCULATION. 88:169-169. Author weblink.
• MAYET J; HUGHES AD; SINCLAIR AM; GEROULAKOS G; MACKAY J; SHAHI M; THOM S; NICOLAIDES A; et alFOALE R; SEVER PS. (1 Oct 1993). VASCULAR AND CARDIAC-HYPERTROPHY ARE RELATED IN HUMAN HYPERTENSION. CIRCULATION. 88:614-614. Author weblink.
• MAYET J; SHAHI M; THOM S; POULTER N; SEVER PS; FOALE RA. (1 Oct 1993). WHY DO BLACK HYPERTENSIVES FARE WORSE. CIRCULATION. 88:511-511. Author weblink.
• Sinclair AM; Hughes AD; Sever PS. (Aug 1993). Effect of nifedipine and glyceryl trinitrate on retinal blood flow in normal subjects. J Hum Hypertens. 7:399-401.
• Hughes AD; Sinclair AM; Geroulakos G; Mayet J; Mackay J; Shahi M; Thom S; Nicolaides A; et alSever PS. (Aug 1993). Structural changes in the heart and carotid arteries associated with hypertension in humans. J Hum Hypertens. 7:395-397.
• Calder JA; Schachter M; Sever PS. (Jun 1993). Ion channel involvement in the acute vascular effects of thiazide diuretics and related compounds. J Pharmacol Exp Ther. 265:1175-1180.
• Garcha RS; Sever PS; Hughes AD. (May 1993). The action of amlodipine on human subcutaneous resistance arteries studied in vitro. J Pharmacol Exp Ther. 265:860-865.
• Sunman W; Martin G; Hair WM; Sever PS; Hughes AD. (Apr 1993). Effect of calcium antagonists on endothelin-induced contraction of isolated human resistance arteries: differences related to site of origin. J Hum Hypertens. 7:189-191.
• CALDER JA; SCHACHTER M; SEVER PS. (1 Apr 1993). INTERACTIONS BETWEEN THIAZIDE DIURETICS AND CYCLIC-NUCLEOTIDES IN ISOLATED SMALL ARTERIES. BRITISH JOURNAL OF PHARMACOLOGY. 108:P154-P154. Author weblink.
• Poulter NR; Sanderson JE; Thompson AV; Sever PS; Chang CL. (6 Mar 1993). Comparison of nifedipine and propranolol as second line agent for hypertension in black Kenyans. BMJ. 306:621-622.
• Sunman W; Hughes AD; Sever PS. (Mar 1993). Free-radical scavengers, thiol-containing reagents and endothelium-dependent relaxation in isolated rat and human resistance arteries. Clin Sci (Lond). 84:287-295.
• CALDER JA; SCHACHTER M; SEVER PS. (1 Dec 1992). IDENTIFICATION OF INDAPAMIDE BINDING-SITES IN GUINEA-PIG RENAL MEMBRANES. BRITISH JOURNAL OF PHARMACOLOGY. 107:P426-P426. Author weblink.
• FLORAS JS; SEVER PS. (1 Dec 1992). PROTECTION DURING THE CRUCIAL HOURS - AMLODIPINE, A NEW CALCIUM-ANTAGONIST IN CARDIOVASCULAR-DISEASE - PROCEEDINGS OF A MEETING HELD IN MONTREAL, JUNE 26, 1990 - INTRODUCTION. JOURNAL OF HUMAN HYPERTENSION. 6:S1-S1. Author weblink.
• WIJETUNGE S; HUGHES AD; SEVER PS. (1 Oct 1992). AMLODIPINE-INDUCED INHIBITION OF CALCIUM-CHANNEL CURRENTS IN SINGLE SMOOTH-MUSCLE CELLS ISOLATED FROM RABBIT EAR ARTERY. BRITISH JOURNAL OF PHARMACOLOGY. 107:P153-P153. Author weblink.
• GARCHA RS; HUGHES AD; SEVER PS. (1 Oct 1992). CYTOSOLIC HEPARIN INHIBITS NORADRENALINE-INDUCED CA2+ RELEASE FROM INTRACELLULAR STORES IN RAT RESISTANCE ARTERIES. BRITISH JOURNAL OF PHARMACOLOGY. 107:P187-P187. Author weblink.
• PARKINSON NA; HUGHES AD; SEVER PS. (1 Oct 1992). PERTUSSIS TOXIN INHIBITION OF ALPHA-2-ADRENERGIC ACTIVITY IN HUMAN ISOLATED RESISTANCE ARTERIES. BRITISH JOURNAL OF PHARMACOLOGY. 107:P186-P186. Author weblink.
• Calder JA; Schachter M; Sever PS. (10 Sep 1992). Direct vascular actions of hydrochlorothiazide and indapamide in isolated small vessels. Eur J Pharmacol. 220:19-26.
• Calder JA; Schachter M; Sever PS. (Jul 1992). Interaction between cicletanine and the eicosanoid system in human subcutaneous resistance arteries. J Pharm Pharmacol. 44:574-578.
• Parkinson NA; Thom SM; Hughes AD; Sever PS; Mulvany MJ; Nielsen H. (Jul 1992). Neurally evoked responses of human isolated resistance arteries are mediated by both alpha 1- and alpha 2-adrenoceptors. Br J Pharmacol. 106:568-573.
• Sunman W; Hughes AD; Sever PS. (16 May 1992). Anaphylactoid response to intravenous acetylcysteine. Lancet. 339:1231-1232.
• Calder JA; Schachter M; Sever PS. (Mar 1992). Mechanisms of action of cicletanine in human and guinea pig resistance arteries. J Cardiovasc Pharmacol. 19:387-393.
• Bain BJ; Rothwell M; Feher MD; Robinson R; Brown J; Sever PS. (Feb 1992). Acute changes in haematological parameters on cessation of smoking. J R Soc Med. 85:80-82.
• Sunman W; Rothwell M; Sever PS. (Feb 1992). Conn's syndrome can cause malignant hypertension. J Hum Hypertens. 6:75-76.
• Sever PS. (9 Nov 1991). Hypertrichosis and verapamil. Lancet. 338:1215-1216.
• Rothwell M; Rampling MW; Cholerton S; Sever PS. (Nov 1991). Haemorheological changes in the very short term after abstention from tobacco by cigarette smokers. Br J Haematol. 79:500-503.
• SEVER PS; POULTER NR; THOM SM; SUNMAN W. (14 Sep 1991). WITHDRAWING ANTIHYPERTENSIVE TREATMENT. BRITISH MEDICAL JOURNAL. 303:643-643. Author weblink.
• Shahi M; Thom S; Poulter N; Sever PS; Foale RA. (Sep 1991). The effects of blood pressure reduction on abnormal left ventricular diastolic function in hypertensive patients. Eur Heart J. 12:974-979.
• SEVER PS. (1 Aug 1991). UNRESOLVED ISSUES IN HYPERTENSION - FOCUS ON AMLODIPINE - INTRODUCTION. JOURNAL OF HUMAN HYPERTENSION. 5:1-1. Author weblink.
• ROSS S; KANNEL WB; NAYER; FERRANNINI E; SEVER PS; CHANG PC; JANSEN; DAWSON; et alFEHER M; NIELSON; LEHTONEN A; NOSADINI R. (1 Apr 1991). PROCEEDINGS OF A SYMPOSIUM - STATES OF INSULIN RESISTANCE - THE INTERACTION BETWEEN HYPERTENSION, GLUCOSE-INTOLERANCE, AND CORONARY HEART-DISEASE - MONTREAL, CANADA JUNE 24, 1990 - DISCUSSION. AMERICAN HEART JOURNAL. 121:1312-1315. Author weblink.
• Martin GN; Thom SA; Sever PS. (Mar 1991). The effects of adenosine triphosphate (ATP) and related purines on human isolated subcutaneous and omental resistance arteries. Br J Pharmacol. 102:645-650.
• Shahi M; Thom S; Poulter N; Sever PS; Foale RA. (Feb 1991). Determinants of left ventricular filling in hypertension. J Hum Hypertens. 5:27-34.
• SEVER PS. (1 Jan 1991). PROCEEDINGS OF A SYMPOSIUM - MANAGEMENT OF CORONARY HEART-DISEASE RISK-FACTORS IN HYPERTENSIVE PATIENTS - CLINICAL-EXPERIENCE WITH DOXAZOSIN, LONDON, ENGLAND, JANUARY 26, 1990 - INTRODUCTION. AMERICAN HEART JOURNAL. 121:245-245. Author weblink DOI.
• SEVER PS; LANGDON CG; GRIMM RH; HOLME IM; NABER FB; POOL JL; POULTER N; TAYLORROBINSON J; et alJONES B; DAVIES HO; KHIMJI HM; RAKHIT AK; PATEL SKC; ANDERSON K; HERNANDEZ R. (1 Jan 1991). PROCEEDINGS OF A SYMPOSIUM - MANAGEMENT OF CORONARY HEART-DISEASE RISK-FACTORS IN HYPERTENSIVE PATIENTS - CLINICAL-EXPERIENCE WITH DOXAZOSIN, LONDON, ENGLAND, JANUARY 26, 1990 - GROUP DISCUSSION. AMERICAN HEART JOURNAL. 121:402-405. Author weblink.
• SEVER PS. (1 Jan 1991). PROCEEDINGS OF A SYMPOSIUM - MANAGEMENT OF CORONARY HEART-DISEASE RISK-FACTORS IN HYPERTENSIVE PATIENTS - CLINICAL-EXPERIENCE WITH DOXAZOSIN, LONDON, ENGLAND, JANUARY 26, 1990 - SUMMARY. AMERICAN HEART JOURNAL. 121:406-406. Author weblink DOI.
• RAMPLING MW; BROWN J; ROBINSON RJ; FEHER MD; CHOLERTON S; SEVER PS. (1 Jan 1991). THE SHORT-TERM EFFECTS OF ABSTENTION FROM TOBACCO BY CIGARETTE SMOKERS ON BLOOD-VISCOSITY AND RELATED PARAMETERS. CLINICAL HEMORHEOLOGY. 11:441-446. Author weblink.
• Schachter M; Gallagher KL; Sever PS. (Dec 1990). Intracellular free magnesium in a vascular smooth muscle cell line. Biochem Soc Trans. 18:1266.
• Schachter M; Gallagher KL; Sever PS. (Dec 1990). Intracellular glutathione and cytosolic calcium responses. Biochem Soc Trans. 18:1185-1186.
• PARKINSON NA; THOM SM; SEVER PS. (1 Nov 1990). ADRENALINE AND NORADRENALINE ACTIVATION OF ALPHA-2-ADRENOCEPTORS IN HUMAN RESISTANCE ARTERIES. BRITISH JOURNAL OF PHARMACOLOGY. 101:P536-P536. Author weblink.
• FEHER MD; HENDERSON A; WADSWORTH J; POULTER C; GELDING S; SEVER PS; RICHMOND W; ELKELES RS. (1 Nov 1990). ADRENERGIC-BLOCKER EFFECTS ON LIPID-METABOLISM IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS (NIDDM). ATHEROSCLEROSIS. 85:95-95. Author weblink DOI.
• SCHACHTER M; MERAJI S; SEVER PS; BRUCKDORFER KR. (1 Nov 1990). LOW-DENSITY LIPOPROTEINS, PLATELETS AND THE VASCULATURE. JOURNAL OF HYPERTENSION. 8:1068-1068. Author weblink DOI.
• Feher MD; Henderson AD; Wadsworth J; Poulter C; Gelding S; Richmond W; Sever PS; Elkeles RS. (Oct 1990). Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. J Hum Hypertens. 4:571-577.
• SEVER PS; REID JL. (1 Oct 1990). RISK-FACTORS FOR CORONARY HEART-DISEASE - SELECTING APPROPRIATE ANTIHYPERTENSIVE THERAPY - INTRODUCTION. JOURNAL OF HUMAN HYPERTENSION. 4:1-1. Author weblink.
• Schachter M; Gallagher KL; Sever PS. (14 Sep 1990). Measurement of intracellular magnesium in a vascular smooth muscle cell line using a fluorescent probe. Biochim Biophys Acta. 1035:378-380.
• Shahi M; Thom S; Poulter N; Sever PS; Foale RA. (25 Aug 1990). Regression of hypertensive left ventricular hypertrophy and left ventricular diastolic function. Lancet. 336:458-461.
• SEVER PS. (7 Jul 1990). ANTIHYPERTENSIVE AND ADVERSE BIOCHEMICAL EFFECTS OF BENDROFLUAZIDE - REPLY. BRITISH MEDICAL JOURNAL. 301:43-43. Author weblink.
• IRIGOINGUICHANDUT M; THOM SM; POTOCNIK SJ; SCHACHTER M; BELCARO G; SEVER PS. (1 Jul 1990). ALPHA-2-ADRENOCEPTORS CONTROL FOREARM SKIN BLOOD-FLOW. EUROPEAN JOURNAL OF PHARMACOLOGY. 183:992-992. Author weblink DOI.
• POTOCNIK SJ; THOM SM; RUTTER PC; SEVER PS. (1 Jul 1990). INVESTIGATION OF OPIATE INTERACTION WITH THE SYMPATHETIC NERVOUS-SYSTEM IN THE HUMAN FOREARM. EUROPEAN JOURNAL OF PHARMACOLOGY. 183:988-989. Author weblink DOI.
• PATEL MK; SCHACHTER M; SEVER PS. (1 Jul 1990). MUSCARINIC RECEPTORS OF HUMAN PROSTATIC STROMAL CELLS-INVITRO. EUROPEAN JOURNAL OF PHARMACOLOGY. 183:1992-1992. Author weblink DOI.
• Poulter NR; Khaw KT; Hopwood BE; Mugambi M; Peart WS; Rose G; Sever PS. (14 Apr 1990). The Kenyan Luo migration study: observations on the initiation of a rise in blood pressure. BMJ. 300:967-972.
• Feher MD; Rampling MW; Brown J; Robinson R; Richmond W; Cholerton S; Bain BJ; Sever PS. (Mar 1990). Acute changes in atherogenic and thrombogenic factors with cessation of smoking. J R Soc Med. 83:146-148.
• Deal JE; Sever PS; Barratt TM; Dillon MJ. (Mar 1990). Phaeochromocytoma--investigation and management of 10 cases. Arch Dis Child. 65:269-274.
• MARTIN GN; THOM SM; SEVER PS. (1 Dec 1989). EFFECTS OF PURINES ON ISOLATED HUMAN RESISTANCE ARTERIES. JOURNAL OF HYPERTENSION. 7:S382-S383. Author weblink.
• Schachter M; Gallagher KL; Patel MK; Sever PS. (Dec 1989). Oxidants and vascular smooth muscle. Biochem Soc Trans. 17:1096-1097.
• HUGHES AD; THOM SM; SCHACTER M; MARTIN GN; WOODALL N; HAIR WM; SEVER PS. (1 Dec 1989). VASOCONSTRICTOR EFFECTS OF ENDOTHELIN IN MAN. JOURNAL OF HYPERTENSION. 7:S373-S373. Author weblink.
• Hughes AD; Nielsen H; Sever PS. (Aug 1989). The effect of atrial natriuretic peptide on human isolated resistance arteries. Br J Pharmacol. 97:1027-1030.
• Nielsen H; Thom SM; Hughes AD; Martin GN; Mulvany MJ; Sever PS. (Jul 1989). Postjunctional alpha 2-adrenoceptors mediate vasoconstriction in human subcutaneous resistance vessels. Br J Pharmacol. 97:829-834.
• Hughes AD; Sever PS. (Jul 1989). The action of dopamine and vascular dopamine (DA1) receptor agonists on human isolated subcutaneous and omental small arteries. Br J Pharmacol. 97:950-956.
• HUGHES AD; SCHACHTER M; PATEL MK; CALLAGHER KL; SEVER PS. (1 Jun 1989). INTRACELLULAR PH AND CALCIUM IN VASCULAR SMOOTH-MUSCLE. BIOCHEMICAL SOCIETY TRANSACTIONS. 17:506-507. Author weblink.
• THOM S; HUGHES AD; WOODALL N; SEVER PS. (1 May 1989). ENDOTHELIN CAUSES PROLONGED VASOCONSTRICTION IN THE HUMAN FOREARM. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 27:P690-P691. Author weblink.
• HUGHES AD; THOM SAM; WOODALL N; SCHACHTER M; HAIR WM; MARTIN GN; SEVER PS. (1 Jan 1989). HUMAN VASCULAR-RESPONSES TO ENDOTHELIN-1 - OBSERVATIONS INVIVO AND INVITRO. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 13:S225-S228. Author weblink DOI.
• SWALES JD; RAMSAY LE; COOPE J; POCOCK SJ; ROBERTSON JIS; SEVER PS; SHAPER AG. (18 Mar 1989). TREATING MILD HYPERTENSION - AGREEMENT FROM THE LARGE TRIALS - REPORT OF THE BRITISH-HYPERTENSION-SOCIETY WORKING PARTY. BRITISH MEDICAL JOURNAL. 298:694-698. Author weblink.
• Sever PS; Poulter NR; Bulpitt CS. (Mar 1989). Double-blind crossover versus parallel groups in hypertension. Am Heart J. 117:735-739.
• Sever PS; Poulter NR. (Feb 1989). A hypothesis for the pathogenesis of essential hypertension: the initiating factors. J Hypertens Suppl. 7:S9-12.
• MILES CMM; SCHACHTER M; SEVER PS. (1 Feb 1989). EFFECTS OF C-18 FATTY-ACIDS ON PHOSPHOINOSITIDE TURNOVER IN CULTURED HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS. BIOCHEMICAL SOCIETY TRANSACTIONS. 17:93-93. Author weblink.
• SEVER PS. (1 Jan 1989). THE RELATIONSHIPS BETWEEN STRUCTURE AND EFFECTS OF ACE INHIBITORS - PAPERS PRESENTED AT A MEETING IN LONDON, FEBRUARY 1989 - OPENING REMARKS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 28:S93-S93. Author weblink.
• Hughes AD; Sever PS. (1989). Action of fenoldopam, a selective dopamine (DA1) receptor agonist, on isolated human arteries. Blood Vessels. 26:119-127.
• RAMPLING MW; FEHER MD; SEVER PS; ELKELES RS. (1 Jan 1989). HEMORHEOLOGICAL DISTURBANCES IN NON-INSULIN-DEPENDENT DIABETES AND THE EFFECTS OF CONCOMITANT HYPERTENSION. CLINICAL HEMORHEOLOGY. 9:101-107. Author weblink.
• Hughes AD; Thom SA; Woodall N; Schachter M; Hair WM; Martin GN; Sever PS. (1989). Human vascular responses to endothelin-1: observations in vivo and in vitro. J Cardiovasc Pharmacol. 13 Suppl 5:S225-S228.
• SEVER PS. (1 Jan 1989). PROCEEDINGS OF A SYMPOSIUM - HYPERTENSION IN THE ELDERLY - FOCUS ON NICARDIPINE - PRESENTED AS A ROUNDTABLE MEETING ON MAY 26, 1988, IN KYOTO, JAPAN - INTRODUCTION. AMERICAN HEART JOURNAL. 117:228-228. Author weblink DOI.
• SEVER PS. (1 Jan 1989). PROCEEDINGS OF A SYMPOSIUM - HYPERTENSION IN THE ELDERLY - FOCUS ON NICARDIPINE - PRESENTED AS A ROUNDTABLE MEETING ON MAY 26, 1988, IN KYOTO, JAPAN - SUMMARY. AMERICAN HEART JOURNAL. 117:273-273. Author weblink DOI.
• SEVER PS; FORETTE F; LITTLER WA; KRAKOFF LR; LEONETTI G; SARUTA T; FLAMM ES; CARRETTA R. (1 Jan 1989). PROCEEDINGS OF A SYMPOSIUM - HYPERTENSION IN THE ELDERLY - FOCUS ON NICARDIPINE - PRESENTED AS A ROUNDTABLE MEETING ON MAY 26, 1988, IN KYOTO, JAPAN - GENERAL GROUP DISCUSSION. AMERICAN HEART JOURNAL. 117:270-272. Author weblink.
• Feher MD; Torrens DJ; Richmond W; Wadsworth J; Sever PS; Elkeles RS. (Dec 1988). Acute lipoprotein changes associated with atenolol therapy for hypertension in non-insulin dependent diabetes. J Hum Hypertens. 2:253-255.
• Feher MD; Rains SG; Richmond W; Torrens D; Wilson G; Wadsworth J; Sever PS; Elkeles RS. (Dec 1988). Beta-blockers, lipoproteins and non-insulin dependent diabetes. Postgrad Med J. 64:926-930.
• FEHER MD; TORRENS DJ; RICHMOND W; WADSWORTH J; SEVER PS; ELKELES RS. (1 Dec 1988). REVERSIBILITY OF LIPOPROTEIN CHANGES INDUCED BY BETA-BLOCKER THERAPY IN NON-INSULIN-DEPENDENT DIABETES. ATHEROSCLEROSIS. 74:251-252. Author weblink DOI.
• Hughes AD; Thom SA; Martin GN; Nielsen H; Hair WM; Schachter M; Sever PS. (Dec 1988). Size and site-dependent heterogeneity of human vascular responses in vitro. J Hypertens Suppl. 6:S173-S175.
• HUGHES AD; THOM SAM; MARTIN GN; NIELSEN H; HAIR WM; SCHACHTER M; SEVER PS. (1 Dec 1988). SIZE-DEPENDENT AND SITE-DEPENDENT HETEROGENEITY OF HUMAN VASCULAR-RESPONSES INVITRO. JOURNAL OF HYPERTENSION. 6:S173-S175. Author weblink.
• Dunn RC; Schachter M; Miles CM; Feher MD; Tranter PR; Bruckdorfer KR; Sever PS. (10 Oct 1988). Low-density lipoproteins increase intracellular calcium in aequorin-loaded platelets. FEBS Lett. 238:357-360.
• Feher MD; Rampling MW; Sever PS; Elkeles RS. (Aug 1988). Diabetic hypertension--the importance of fibrinogen and blood viscosity. J Hum Hypertens. 2:117-122.
• FEHER MD; LUCAS RA; FARID NA; IDLE J; BERGSTROM RF; LEMBERGER L; SEVER PS. (1 Aug 1988). SINGLE DOSE PHARMACOKINETICS OF TOMOXETINE IN POOR AND EXTENSIVE METABOLIZERS OF DEBRISOQUINE. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 26:P231-P231. Author weblink.
• Floras JS; Hassan MO; Jones JV; Osikowska BA; Sever PS; Sleight P. (Jul 1988). Consequences of impaired arterial baroreflexes in essential hypertension: effects on pressor responses, plasma noradrenaline and blood pressure variability. J Hypertens. 6:525-535.
• POULTER NR; KHAW KT; SEVER PS. (1 Jul 1988). HIGHER BLOOD PRESSURES OF URBAN MIGRANTS FROM AN AFRICAN LOW BLOOD PRESSURE POPULATION ARE NOT DUE TO SELECTIVE MIGRATION. AMERICAN JOURNAL OF HYPERTENSION. 1:S143-S145. Author weblink.
• Poulter NR; Khaw KT; Sever PS. (Jul 1988). Higher blood pressures of urban migrants from an African low-blood pressure population are not due to selective migration. Am J Hypertens. 1:143S-145S.
• DUNN RC; SCHACHTER M; MILES CMM; FEHER MD; BRUCKDORFER KR; SEVER PS. (1 Jun 1988). LOW-DENSITY LIPOPROTEINS INCREASE INTRACELLULAR CALCIUM IN HUMAN-PLATELETS. BIOCHEMICAL SOCIETY TRANSACTIONS. 16:287-288. Author weblink.
• MILES CMM; SCHACHTER M; DUNN RC; SEVER PS. (1 Jun 1988). OLEIC-ACID STIMULATES PHOSPHOINOSITIDE TURNOVER IN HUMAN-PLATELETS. BIOCHEMICAL SOCIETY TRANSACTIONS. 16:288-288. Author weblink.
• OATES NS; FEHER MD; PERRY HE; SCHMID BJ; SEVER PS; IDLE J. (1 May 1988). INFLUENCE OF QUINIDINE ON NIFEDIPINE PLASMA PHARMACOKINETICS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 25:P675-P675. Author weblink.
• Feher MD; Torrens D; Richmond W; Sever PS; Elkeles RS. (Mar 1988). Comparison between oral and intravenous fat tolerance tests in normolipidaemic subjects. Horm Metab Res. 20:182-183. DOI.
• Winter RJ; Inkpen PM; Dickinson KE; Rudd RM; Sever PS. (Mar 1988). De novo cardiac beta adrenoceptor synthesis in adult rats under normoxic and hypoxic conditions. Cardiovasc Res. 22:159-162.
• Floras JS; Hassan MO; Jones JV; Osikowska BA; Sever PS; Sleight P. (Mar 1988). Factors influencing blood pressure and heart rate variability in hypertensive humans. Hypertension. 11:273-281.
• Schachter M; Sever PS. (27 Feb 1988). Peripheral adrenoceptors and type A behaviour. Lancet. 1:478-479.
• Sever PS; Poulter NR. (Dec 1987). Calcium antagonists and diuretics as combined therapy. J Hypertens Suppl. 5:S123-S126.
• Sever PS. (Dec 1987). Current opinion on the management of hypertension and cardiovascular risk factors. Br J Clin Pract Suppl. 54:2-8.
• Thom S; Hughes A; Martin G; Sever PS. (Nov 1987). Endothelium-dependent relaxation in isolated human arteries and veins. Clin Sci (Lond). 73:547-552.
• POULTER N; THOMPSON AV; SEVER PS. (1 Jan 1987). A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER TRIAL TO INVESTIGATE THE ADDITIVE HYPOTENSIVE EFFECT OF A DIURETIC (MEFRUSIDE) TO THAT PRODUCED BY NIFEDIPINE. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 10:S53-S56. Author weblink DOI.
• Hill H; Geraghty I; Hughes A; Sever PS; Schachter M. (Oct 1987). Ergometrine and bronchospasm. Anaesthesia. 42:1115-1116.
• WINTER RJD; DICKINSON KEJ; RUDD RM; SEVER PS. (1 Sep 1987). DENOVO BETA-ADRENOCEPTOR SYNTHESIS IN ADULT-RAT LUNG - AN INVIVO STUDY. THORAX. 42:747-748. Author weblink.
• Thom SM; Hughes AD; Goldberg P; Martin G; Schachter M; Sever PS. (Aug 1987). The actions of calcitonin gene related peptide and vasoactive intestinal peptide as vasodilators in man in vivo and in vitro. Br J Clin Pharmacol. 24:139-144.
• Hughes AD; Thom SA; Woodall NM; Redman D; Sever PS. (Jun 1987). Dopamine produces forearm vasodilatation following alpha-adrenoceptor blockade by an action on vascular dopamine (DA1) receptors in man. J Hypertens. 5:337-340.
• Erne P; Schachter M; Fabbro D; Miles CM; Sever PS. (29 May 1987). Calcium transients in human platelets monitored by aequorin, fura-2 and quin-2: effects of protein kinase C activation and inhibition. Biochem Biophys Res Commun. 145:66-72.
• Poulter N; Thompson AV; Sever PS. (1987). A double-blind, placebo-controlled, crossover trial to investigate the additive hypotensive effect of a diuretic (mefruside) to that produced by nifedipine. J Cardiovasc Pharmacol. 10 Suppl 10:S53-S56.
• Schachter M; Miles CM; Leys K; Sever PS. (1987). Characterization of neuropeptide Y receptors in rabbit kidney: preliminary comparisons with rat and human kidney. J Cardiovasc Pharmacol. 10 Suppl 12:S157-S162.
• SCHACHTER M; MILES CMM; SEVER PS; LEYS K. (1 Dec 1986). CHARACTERIZATION OF NEUROPEPTIDE-Y RECEPTORS IN RABBIT KIDNEY - PRELIMINARY COMPARISON WITH HUMAN AND RAT-KIDNEY. JOURNAL OF HYPERTENSION. 4:795-795. Author weblink DOI.
• POULTER N; THOMPSON AV; SEVER PS. (1 Dec 1986). DO DIURETICS ENHANCE THE HYPOTENSIVE EFFECT OF NIFEDIPINE - A DOUBLE-BLIND CROSSOVER TRIAL IN BLACK HYPERTENSIVE PATIENTS. JOURNAL OF HYPERTENSION. 4:792-793. Author weblink DOI.
• Poulter NR; Sever PS. (Dec 1986). Moderate potassium supplementation: ineffective in black normotensives. East Afr Med J. 63:798-802.
• McKernan RM; Dickinson KE; Miles CM; Sever PS. (15 Oct 1986). Heterogeneity between soluble human and rabbit splenic alpha 2-adrenoceptors. Biochem Pharmacol. 35:3517-3523.
• Dickinson KE; Schachter M; Miles CM; Coy DH; Sever PS. (Sep 1986). Characterization of vasoactive intestinal peptide (VIP) receptors in mammalian lung. Peptides. 7:791-800.
• GOLDBERG PL; HUGHES AD; SEVER PS. (1 Sep 1986). THE EFFECT OF INFLATION OF AN ANTI-GRAVITY SUIT ON FOREARM VASCULATURE. JOURNAL OF PHYSIOLOGY-LONDON. 378:P93-P93. Author weblink.
• Morice AH; Schofield P; Keal EE; Sever PS. (Aug 1986). A comparison of the ventilatory, cardiovascular and metabolic effects of salbutamol, aminophylline and vasoactive intestinal peptide in normal subjects. Br J Clin Pharmacol. 22:149-153.
• Floras J; Vann Jones J; Hassan MO; Osikowska BA; Sever PS; Sleight P. (Aug 1986). Failure of plasma norepinephrine to consistently reflect sympathetic activity in humans. Hypertension. 8:641-649.
• Dunn GD; Brown MJ; Sapsford RN; Mansfield AO; Hemingway AP; Sever PS; Allison DJ. (10 May 1986). Functioning middle mediastinal paraganglioma (phaeochromocytoma) associated with intercarotid paragangliomas. Lancet. 1:1061-1064.
• BECKET AJ; EACOTT DW; GOLDBERG PL; SEVER PS; THOM S. (1 May 1986). A VACUUM CHAMBER FOR THE APPLICATION OF LOWER-BODY NEGATIVE-PRESSURE TO HUMAN-SUBJECTS. JOURNAL OF PHYSIOLOGY-LONDON. 374:P10-P10. Author weblink.
• Leys K; Morice AH; Madonna O; Sever PS. (21 Apr 1986). Autoradiographic localisation of VIP receptors in human lung. FEBS Lett. 199:198-202.
• Schachter M; Dickinson KE; Miles CM; Sever PS. (7 Apr 1986). Characterisation of a high-affinity VIP receptor in human lung parenchyma. FEBS Lett. 199:125-129.
• SEVER PS. (1 Apr 1986). 1985 - THE YEAR OF THE HYPERTENSION TRIALS - INTERPRETING THE RESULTS. TRENDS IN PHARMACOLOGICAL SCIENCES. 7:134-139. Author weblink DOI.
• DICKINSON KEJ; SCHACHTER M; MILES CMM; SEVER PS. (1 Apr 1986). CHARACTERIZATION OF VASOACTIVE-INTESTINAL-PEPTIDE (VIP) RECEPTORS IN MAMMALIAN LUNG. AMERICAN REVIEW OF RESPIRATORY DISEASE. 133:A141-A141. Author weblink.
• WINTER RJD; INKPEN PM; RUDD RM; SEVER PS; DICKINSON KEJ. (1 Apr 1986). CHRONIC HYPOXIA REDUCES THE RESPONSE OF BETA-ADRENERGIC RECEPTORS TO DOWN-REGULATION WITH AGONIST. AMERICAN REVIEW OF RESPIRATORY DISEASE. 133:A141-A141. Author weblink.
• LEYS K; MORICE AH; HUGHES AD; SCHACHTER M; DICKINSON KEJ; SEVER PS. (1 Apr 1986). LOCALIZATION OF VIP RECEPTORS IN HUMAN-LUNG BY LIGHT-MICROSCOPE AUTORADIOGRAPHY. AMERICAN REVIEW OF RESPIRATORY DISEASE. 133:A141-A141. Author weblink.
• MARTIN G; HUGHES A; MORICE AH; SCHACHTER M; SEVER PS. (1 Mar 1986). POTENTIATING EFFECT OF FORSKOLIN ON ISOPRENALINE IN ISOLATED TRACHEA. THORAX. 41:242-242. Author weblink.
• WINTER RJD; RUDD RM; SEVER PS; DICKINSON KEJ. (1 Mar 1986). THE EFFECT OF ISOPRENALINE ON BETA-ADRENOCEPTOR NUMBER IN PERIPHERAL TISSUE FOLLOWING CHRONIC HYPOXIA IN RATS. THORAX. 41:249-249. Author weblink.
• Barrowcliffe MP; Morice A; Jones JG; Sever PS. (Feb 1986). Pulmonary clearance of vasoactive intestinal peptide. Thorax. 41:88-93.
• Winter RJ; Dickinson KE; Rudd RM; Sever PS. (Feb 1986). Tissue specific modulation of beta-adrenoceptor number in rats with chronic hypoxia with an attenuated response to down-regulation by salbutamol. Clin Sci (Lond). 70:159-165.
• Dickinson KE; McKernan RM; Miles CM; Leys KS; Sever PS. (29 Jan 1986). Heterogeneity of mammalian alpha 2-adrenoceptors delineated by [3H]yohimbine binding. Eur J Pharmacol. 120:285-293.
• Morice AH; Sever PS. (1986). Vasoactive intestinal peptide as a bronchodilator in severe asthma. Peptides. 7 Suppl 1:279-280.
• MORICE AH; SEVER PS. (1 Jan 1986). VASOACTIVE-INTESTINAL-PEPTIDE AS A BRONCHODILATOR IN SEVERE ASTHMA. PEPTIDES. 7:279-280. Author weblink DOI.
• Poulter NR; Khaw K; Hopwood BE; Mugambi M; Peart WS; Sever PS. (Dec 1985). Determinants of blood pressure changes due to urbanization: a longitudinal study. J Hypertens Suppl. 3:S375-S377.
• Bradley T; Hjemdahl P; DiBona GF; Osikowska BA; Sever PS; Goldberg LI. (Dec 1985). Evidence against a functional role for dopamine-4-sulphate in the kidney. Acta Physiol Scand. 125:739-741.
• Redman D; Thom SA; Hughes AD; Hasan S; Sever PS. (Dec 1985). Human vasodilator responses to a dopamine agonist: possible mechanisms. J Hypertens Suppl. 3:S177-S178.
• BARROWCLIFFE MP; MORICE A; JONES JG; SEVER PS. (1 Jan 1985). PULMONARY CLEARANCE OF VASOACTIVE INTESTINAL PEPTIDE IN THE RAT. CLINICAL SCIENCE. 69:P20-P20. Author weblink.
• Thom SA; Hughes AD; Martin GN; Sever PS. (Dec 1985). The release of the endothelium derived relaxing factor from isolated human arteries. J Hypertens Suppl. 3:S97-S99.
• DICKINSON KEJ; MCKERNAN RM; SEVER PS. (1 Jan 1985). DO HUMAN ALPHA-2-ADRENOCEPTORS DIFFER FROM THOSE OF OTHER MAMMALIAN-SPECIES. CLINICAL SCIENCE. 68:P22-P22. Author weblink.
• THOM S; HAYES R; CALVETE J; SEVER PS. (1 Jan 1985). INVIVO AND INVITRO STUDIES OF ALPHA-2ADRENOCEPTOR RESPONSES IN HUMAN VASCULAR SMOOTH-MUSCLE. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 7:S137-S143. Author weblink.
• Poulter NR; Khaw KT; Mugambi M; Peart WS; Sever PS. (May 1985). Migration-induced changes in blood pressure: a controlled longitudinal study. Clin Exp Pharmacol Physiol. 12:211-216.
• MORICE AH; SCHOFIELD PM; SEVER PS; KEAL EE. (1 Jan 1985). A COMPARISON OF THE EFFECT OF AMINOPHYLLINE AND SALBUTAMOL ON MINUTE VENTILATION AND THE VENTILATORY RESPONSE TO CARBON-DIOXIDE. THORAX. 40:234-234. Author weblink.
• Thom S; Hayes R; Calvete J; Sever PS. (1985). In vivo and in vitro studies of alpha 2-adrenoceptor responses in human vascular smooth muscle. J Cardiovasc Pharmacol. 7 Suppl 6:S137-S143.
• MORICE AH; SEVER PS. (1 Jan 1985). THE EFFECT OF INTRAVENOUS VIP FOLLOWING CHOLINERGIC BLOCKADE. THORAX. 40:714-714. Author weblink.
• Poulter N; Khaw KT; Hopwood BE; Mugambi M; Peart WS; Rose G; Sever PS. (Nov 1984). Blood pressure and associated factors in a rural Kenyan community. Hypertension. 6:810-813.
• Poulter N; Khaw KT; Hopwood BE; Mugambi M; Peart WS; Rose G; Sever PS. (Sep 1984). Blood pressure and its correlates in an African tribe in urban and rural environments. J Epidemiol Community Health. 38:181-185.
• Mathias CJ; Unwin RJ; Pike FA; Frankel HL; Sever PS; Peart WS. (May 1984). The immediate pressor response to saralasin in man: evidence against sympathetic activation and for intrinsic angiotensin II-like myotropism. Clin Sci (Lond). 66:517-524.
• Morice AH; Unwin RJ; Sever PS. (Mar 1984). Vasoactive intestinal peptide as a bronchodilator in asthmatic subjects. Peptides. 5:439-440.
• MORICE A; UNWIN RJ; SEVER PS. (1 Jan 1984). INVIVO BRONCHODILATOR ACTIVITY OF VASOACTIVE INTESTINAL PEPTIDE IN THE CAT. AMERICAN REVIEW OF RESPIRATORY DISEASE. 129:882-882. Author weblink.
• Poulter N; Khaw KT; Hopwood BE; Mugambi M; Peart WS; Sever PS. (1984). Salt and blood pressure in various populations. J Cardiovasc Pharmacol. 6 Suppl 1:S197-S203.
• POULTER N; KHAW KT; HOPWOOD BEC; MUGAMBI M; PEART WS; SEVER PS. (1 Jan 1984). SALT AND BLOOD-PRESSURE IN VARIOUS POPULATIONS. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 6:S197-S203. DOI.
• MORICE AH; UNWIN RJ; SEVER PS. (1 Jan 1984). THE BRONCHODILATING EFFECTS OF INTRAVENOUS VASOACTIVE INTESTINAL PEPTIDE IN HUMAN ASTHMATIC SUBJECTS. CLINICAL SCIENCE. 66:P58-P58. Author weblink.
• MORICE A; SEVER PS. (1 Jan 1984). USE OF VASOACTIVE INTESTINAL PEPTIDE IN SEVERE ACUTE ASTHMA. THORAX. 39:707-707. Author weblink.
• Snell ME; Lawrence R; Sutton D; Sever PS; Peart WS. (Dec 1983). Advances in the techniques of localisation of adrenal tumours and their influence on the surgical approach to the tumour. Br J Urol. 55:617-621.
• Mathias CJ; Wilkinson AH; Pike FA; Sever PS; Peart WS. (Dec 1983). Clonidine in unilateral renal artery stenosis and unilateral renal parenchymal disease--similar antihypertensive but different renin suppressive effects. J Hypertens Suppl. 1:123-125.
• Morice A; Unwin RJ; Sever PS. (26 Nov 1983). Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet. 2:1225-1227.
• Luck P; Mikhailidis DP; Dashwood MR; Barradas MA; Sever PS; Dandona P; Wakeling A. (Nov 1983). Platelet hyperaggregability and increased alpha-adrenoceptor density in anorexia nervosa. J Clin Endocrinol Metab. 57:911-914.
• Idle JR; Sever PS. (18 Jun 1983). Treatment of angina pectoris with nifedipine. Br Med J (Clin Res Ed). 286:1978-1979.
• SEVER PS. (1 Jan 1983). NON-PHARMACOLOGICAL CONTROL OF BLOOD-PRESSURE. POSTGRADUATE MEDICAL JOURNAL. 59:127-130.
• Mathias CJ; Wilkinson A; Lewis PS; Peart WS; Sever PS; Snell ME. (Feb 1983). Clonidine lowers blood pressure independently of renin suppression in patients with unilateral renal artery stenosis. Chest. 83:357-359.
• DASHWOOD MR; LUCK P; SEVER PS; WAKELING A. (1 Jan 1983). INCREASED PLATELET ALPHA-RECEPTOR DENSITIES IN THE CACHECTIC PHASE OF ANOREXIA-NERVOSA. JOURNAL OF PHYSIOLOGY-LONDON. 336:P50-P50. Author weblink.
• Sever PS. (1983). Non-pharmacological control of blood pressure. Postgrad Med J. 59 Suppl 3:127-130.
• Osikowska BA; Idle JR; Swinbourne FJ; Sever PS. (1 Jul 1982). Unequivocal synthesis and characterisation of dopamine 3- and 4-O-sulphates. Biochem Pharmacol. 31:2279-2284.
• DAVIES IB; MATHIAS CJ; SUDERA D; SEVER PS. (1 Jan 1982). AGONIST REGULATION OF ALPHA-ADRENERGIC RECEPTOR RESPONSES IN MAN. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 4:S139-S144. Author weblink DOI.
• Davies IB; Mathias CJ; Sudera D; Sever PS. (1982). Agonist regulation of alpha-adrenergic receptor responses in man. J Cardiovasc Pharmacol. 4 Suppl 1:S139-S144.
• OSIKOWSKA BA; IDLE J; SWINBOURNE FJ; SEVER PS. (1 Jan 1982). UNEQUIVOCAL SYNTHESIS AND CHARACTERIZATION OF DOPAMINE 3-O-SULFATE AND 4-O-SULFATES. BIOCHEMICAL PHARMACOLOGY. 31:2279-2284. Author weblink DOI.
• Davies IB; Sudera D; Sever PS. (Dec 1981). Endogenous agonist regulation of alpha-adrenoceptors in man. Clin Sci (Lond). 61 Suppl 7:207s-210s.
• Frier BM; Corrall RJ; Pritchard JL; Sever PS. (Aug 1981). Changes in plasma renin activity after hypoglycaemia in sympathectomized man. Clin Sci (Lond). 61:245-247.
• Floras JS; Jones JV; Hassan MO; Osikowska B; Sever PS; Sleight P. (18 Jul 1981). Cuff and ambulatory blood pressure in subjects with essential hypertension. Lancet. 2:107-109.
• Wilcox CS; Lewis PS; Peart WS; Sever PS; Osikowska BA; Suddle SA; Bluhm MM; Veall N; et alLancaster R. (May 1981). Renal function, body fluid volumes, renin, aldosterone, and noradrenaline during treatment of hypertension with pindolol. J Cardiovasc Pharmacol. 3:598-611.
• Wilcox CS; Lewis PS; Sever PS; Peart WS. (Apr 1981). The actions of saralasin on the renal circulation of man and dog; evidence for a sympathetic neural component to vasoconstriction. Eur J Clin Invest. 11:77-83.
• Lightman SL; James VH; Linsell C; Mullen PE; Peart WS; Sever PS. (Mar 1981). Studies of diurnal changes in plasma renin activity, and plasma noradrenaline, aldosterone and cortisol concentrations in man. Clin Endocrinol (Oxf). 14:213-223.
• Bannister R; Boylston AW; Davies IB; Mathias CJ; Sever PS; Sudera D. (1981). beta-Receptor numbers and thermodynamics in denervation supersensitivity. J Physiol. 319:369-377.
• DAVIES IB; SUDERA D; SEVER PS. (1 Jan 1981). ENDOGENOUS AGONIST REGULATION OF ALPHA-ADRENOCEPTORS IN MAN. CLINICAL SCIENCE. 61:S207-S210. Author weblink.
• MATHIAS CJ; UNWIN RJ; FRANKEL HL; DAVIES IB; SEVER PS; PEART WS. (1 Jan 1981). MECHANISM OF THE IMMEDIATE PRESSOR-RESPONSE TO SARALASIN - STUDIES IN TETRAPLEGIC MAN. CLINICAL SCIENCE. 61:P37-P37. Author weblink.
• IDLE J; OSIKOWSKA BA; SEVER PS; SWINBOURNE FJ. (1 Jan 1981). PITFALLS IN THE SYNTHESIS AND AUTHENTICATION OF DOPAMINE-ORTHOSULFATES. BRITISH JOURNAL OF PHARMACOLOGY. 74:P837-P838. Author weblink.
• BANNISTER R; DAVIES IB; FRANKEL HL; MATHIAS CJ; PEART WS; SEVER PS; SUDERA D. (1 Jan 1981). PLATELET ALPHA-RECEPTOR PROPERTIES AND PRESSOR-RESPONSES TO NORADRENALINE IN TETRAPLEGIA COMPARED WITH MULTIPLE SYSTEM ATROPHY. JOURNAL OF PHYSIOLOGY-LONDON. 312:P25-P26. Author weblink.
• SEVER PS. (1 Jan 1981). RACIAL-DIFFERENCES IN BLOOD-PRESSURE - GENETIC AND ENVIRONMENTAL-FACTORS. POSTGRADUATE MEDICAL JOURNAL. 57:755-759. Author weblink.
• Mullen PE; Lightman S; Linsell C; McKeon P; Sever PS; Todd K. (1981). Rhythms of plasma noradrenaline in man. Psychoneuroendocrinology. 6:213-222.
• Sever PS; Roberts JC; Snell ME. (Nov 1980). Phaeochromocytoma. Clin Endocrinol Metab. 9:543-568.
• Gordon D; Roddis SA; Sever PS. (Oct 1980). Effect of propranolol on heart rate, blood pressure and plasma noradrenaline during coitus in the rabbit. Clin Sci (Lond). 59:231-236.
• Davies IB; Bannister R; Hensby C; Sever PS. (Sep 1980). The pressor actions of noradrenaline and angiotension II in chronic autonomic failure treated with indomethacin. Br J Clin Pharmacol. 10:223-229.
• Sever PS; Gordon D; Peart WS; Beighton P. (12 Jul 1980). Blood-pressure and its correlates in urban and tribal Africa. Lancet. 2:60-64.
• Moss S; Greenbaum R; Sever PS. (Feb 1980). Preoperative localization of a phaeochromocytoma using plasma noradrenaline concentrations in multiple-site samples. J R Soc Med. 73:139-141.
• Davies IB; Bannister R; Sever PS. (19 Jan 1980). Indomethacin treatment of postural hypotension in autonomic failure. Br Med J. 280:181.
• DAVIES IB; MATHIAS CJ; SUDERA D; LETHBRIDGE K; BANNISTER R; BOYLSTON A; SEVER PS. (1 Jan 1980). CHARACTERIZATION OF ALPHA-ADRENORECEPTORS AND BETA-ADRENORECEPTORS IN DENERVATION SUPER-SENSITIVITY IN MAN. CLINICAL SCIENCE. 59:P2-P3. Author weblink.
• COPE L; DAVIES IB; LIGHTMAN SL; SEVER PS. (1 Jan 1980). COMPARISON OF THE KINETICS OF INFUSED WITH EXERCISE-RELEASED PLASMA NORADRENALINE IN MAN. CLINICAL SCIENCE. 59:P3-P3. Author weblink.
• BANNISTER R; DAVIES IB; HOLLY E; LETHBRIDGE K; MATHIAS CJ; SEVER PS; SUDERA D. (1 Jan 1980). DIFFERENT ALPHA-RECEPTOR PROPERTIES AND BAROREFLEX LOSS IN ALPHA-ADRENERGIC DENERVATION SUPER-SENSITIVITY IN MAN. JOURNAL OF PHYSIOLOGY-LONDON. 308:P44-P45. Author weblink.
• DAVIES IB; BANNISTER R; SEVER PS. (1 Jan 1980). INDOMETHACIN TREATMENT OF POSTURAL HYPOTENSION IN AUTONOMIC FAILURE. BRITISH MEDICAL JOURNAL. 280:181-181. Author weblink.
• Davies IB; Sever PS; Rosenthal T. (Jul 1979). Sympathetic reflex responses during treatment of essential hypertension with hydrallazine and oxprenolol. Br J Clin Pharmacol. 8:49-51.
• Floras JS; Hassan MO; Jones JV; Sever PS; Sleight P; Turner KL. (Jun 1979). Baroreflex sensitivity and plasma noradrenaline concentration in relation to the blood pressure during dynamic exercise in hypertension [proceedings]. J Physiol. 291:44P-45P.
• Sever PS. (10 Feb 1979). False transmitters and migraine. Lancet. 1:333.
• FLORAS JS; HASSAN MO; JONES JV; SEVER PS; SLEIGHT P; TURNER KL. (1 Jan 1979). BAROREFLEX SENSITIVITY AND PLASMA NORADRENALINE CONCENTRATION IN RELATION TO THE BLOOD-PRESSURE DURING DYNAMIC EXERCISE IN HYPERTENSION. JOURNAL OF PHYSIOLOGY-LONDON. 291:P44-P45. Author weblink.
• FRIER BM; CORRALL RJM; ASHBY JP; MCCLEMONT EJW; SEVER PS. (1 Jan 1979). EFFECT OF PREGANGLIONIC SYMPATHECTOMY ON METABOLIC RECOVERY FROM HYPOGLYCEMIA. CLINICAL SCIENCE. 57:P24-P24. Author weblink.
• Sever PS; Peart WS; Meade TW; Davies IB; Gordon D. (1979). Ethnic differences in blood pressure with observations on noradrenaline and renin. 1. A working population. Clin Exp Hypertens. 1:733-744.
• Sever PS; Peart WS; Davies IB; Tunbridge RD; Gordon D. (1979). Ethnic differences in blood pressure with observations on noradrenaline and renin. A hospital hypertensive population. Clin Exp Hypertens. 1:745-760.
• SEVER PS. (1 Jan 1979). FALSE TRANSMITTERS AND MIGRAINE. LANCET. 1:333-333. Author weblink.
• FLORAS JS; HASSAN MO; JONES JV; SEVER PS; SLEIGHT P; TURNER KL. (1 Jan 1979). PLASMA NORADRENALINE CONCENTRATIONS DURING ISOMETRIC AND DYNAMIC EXERCISE IN ESSENTIAL HYPERTENSION. BRITISH HEART JOURNAL. 42:232-232. Author weblink.
• Sever PS; Peart WS; Meade TW; Davies IB; Gordon D; Tunbridge RD. (Dec 1978). Are racial differences in essential hypertension due to different pathogenetic mechanisms?. Clin Sci Mol Med Suppl. 4:383s-386s.
• Davies IB; Bannister RG; Sever PS; Wilcox CS. (Nov 1978). Fludrocortisone in the treatment of postural hypotension: altered sensitivity to pressor agents [proceedings]. Br J Clin Pharmacol. 6:444P-445P.
• Vecht RJ; Graham GW; Sever PS. (Nov 1978). Plasma noradrenaline concentrations during isometric exercise. Br Heart J. 40:1216-1220.
• Rosenthal T; Birch M; Osikowska B; Sever PS. (Mar 1978). Changes in plasma noradrenaline concentration following sympathetic stimulation by gradual tilting. Cardiovasc Res. 12:144-147.
• SEVER PS; PEART WS; MEADE TW; DAVIES IB; GORDON D; TUNBRIDGE RDG. (1 Jan 1978). ARE RACIAL-DIFFERENCES IN ESSENTIAL HYPERTENSION DUE TO DIFFERENT PATHOGENETIC MECHANISMS. CLINICAL SCIENCE AND MOLECULAR MEDICINE. 55:S383-S386. Author weblink.
• DAVIES IB; BANNISTER RG; SEVER PS; WILCOX CS. (1 Jan 1978). FLUDROCORTISONE IN TREATMENT OF POSTURAL HYPOTENSION - ALTERED SENSITIVITY TO PRESSOR AGENTS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 6:P444-P445. Author weblink.
• Sever PS; Osikowska B; Birch M; Tunbridge RD. (21 May 1977). Plasma-noradrenaline in essential hypertension. Lancet. 1:1078-1081.
• Sever PS. (26 Mar 1977). Hypertensive crisis in patients with phaeochromocytoma given metoclopramide. Lancet. 1:703.
• SEVER PS. (1 Jan 1977). HYPERTENSIVE CRISIS IN PATIENTS WITH PHEOCHROMOCYTOMA GIVEN METOCLOPRAMIDE. LANCET. 1:703-703. Author weblink.
• Gordon D; Sever PS. (28 Aug 1976). On the fourth cranial nerve. Lancet. 2:466.
• Sever PS; Dring LG; Williams RT. (Jun 1976). Urinary metabolites of p-hydroxyamphetamine in man, rat and guinea-pig. Xenobiotica. 6:345-353. DOI.
• Sever PS. (7 Feb 1976). Receptor sensitivity in schizophrenia. Lancet. 1:312.
• Sever PS; Caldwell J; Williams RT. (Feb 1976). Tolerance to amphetamine in two species (rat and guinea pig) that metabolize it differently. Psychol Med. 6:35-42.
• GORDON D; SEVER PS. (1 Jan 1976). 4TH CRANIAL NERVE. LANCET. 2:466-466. Author weblink.
• OSIKOWSKA BA; SEVER PS. (1 Jan 1976). ALTERATIONS IN PLASMA NORADRENALINE CONCENTRATION IN RESPONSE TO POSTURAL CHANGE IN NORMAL SUBJECTS, IN PATIENTS WITH AUTONOMIC FAILURE AND IN ESSENTIAL HYPERTENSION. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 3:P963-P964. Author weblink.
• SEVER PS. (1 Jan 1976). BLOOD-PRESSURE. LANCET. 1:1404-1404. Author weblink.
• SEVER PS. (1 Jan 1976). RECEPTOR SENSITIVITY IN SCHIZOPHRENIA. LANCET. 1:312-312. Author weblink.
• Sever PS; Dring LG; Williams RT. (19 Dec 1975). The metabolism of (-)-ephedrine in man. Eur J Clin Pharmacol. 9:193-198.
• Caldwell J; Sever PS. (Dec 1974). The biochemical pharmacology of abused drugs. III. Cannabis, opiates, and synthetic narcotics. Clin Pharmacol Ther. 16:989-1013.
• Caldwell J; Sever PS. (Nov 1974). The biochemical pharmacology of abused drugs. II. Alcohol and barbiturates. Clin Pharmacol Ther. 16:737-749.
• Sever PS; Caldwell J; Williams RT. (Oct 1974). Evidence against the involvement of false neurotransmitters in tolerance to amphetamine-induced hyperthermia in the rat. J Pharm Pharmacol. 26:823-826.
• Caldwell J; Sever PS; Trelinski M. (Oct 1974). On the mechanism of the hyperthermia induced by amphetamine in the rat. J Pharm Pharmacol. 26:821-823.
• Caldwell J; Sever PS. (Oct 1974). The biochemical pharmacology of abused drugs. I. Amphetamines, cocaine, and LSD. Clin Pharmacol Ther. 16:625-638.
• Sever PS; Trelinski M. (Aug 1974). The effects of indomethacin on the development of tolerance to amphetamine-induced hyperthermia. Are prostaglandins involved?. J Pharm Pharmacol. 26:655-657.
• CALDWELL J; SEVER PS. (1 Jan 1974). EVIDENCE AGAINST A ROLE FOR PARA HYDROXY-NOREPHEDRINE IN AMPHETAMINE TOLERANCE. JOURNAL DE PHARMACOLOGIE. 5:14-14. Author weblink.
• SEVER PS; CALDWELL J. (1 Jan 1974). SPECIES-DIFFERENCES IN AMPHETAMINE TOLERANCE. JOURNAL DE PHARMACOLOGIE. 5:91-91. Author weblink.
• CALDWELL J; SEVER PS; TRELINSK M. (1 Jan 1974). MECHANISM OF HYPERTHERMIA INDUCED BY AMPHETAMINE IN RAT. JOURNAL OF PHARMACY AND PHARMACOLOGY. 26:821-823. Author weblink.
• Sever PS; Caldwell J; Dring LG; Williams RT. (Oct 1973). The metabolism of amphetamine in dependent subjects. Eur J Clin Pharmacol. 6:177-180.
• Wynn RM; Sever PS; Hellman LM. (1 Oct 1967). Morphologic studies of the ruptured amnion. Am J Obstet Gynecol. 99:359-367.
• FEHER MD; RICHMOND W; TORRENS D; GIBBONS A; SEVER PS; ELKELES RS. (1 Jan 1987). COMPARISON BETWEEN ORAL AND INTRAVENOUS FAT TOLERANCE-TESTS IN NORMAL SUBJECTS. CLINICAL SCIENCE. 72:P25-P25. Author weblink.

Chapters in books

• Sever P. Therapeutic intervention to prevent coronary heart disease and stroke. In Horizons in Medicine 15. 263-272. Weber J (ed). Royal College of Physicians of London, London (2003).

Conferences

• Sever PS; Poulter NR; Chang C-L; Thom SA; Hughes AD; Welsh P; Sattar N. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): Testing C-Reactive Protein at Baseline and on-Treatment as an Independent Predictor of Cardiovascular Outcomes. American-Heart-Association Scientific Sessions 2010 on Resuscitation Science Symposium, 13 Nov 2010 - 17 Nov 2010. 122:2219-2219. LIPPINCOTT WILLIAMS & WILKINS (23 Nov 2010). Author weblink.
• Christofi F; Wijetunge S; Sever PS; Hughes AD. Expression and function of the tissue renin-angiotensin system in human vascular smooth muscle cells in culture. Conference on Frontiers in Cardiovascular Biology, 16 Jul 2010 - 19 Jul 2010. 87:S60-S60. OXFORD UNIV PRESS (1 Jul 2010).
• Lindgren P; Eriksson J; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; et alJonsson B. The Economic Consequences of Non-Adherence to Lipid-Lowering Therapy: Results From the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). 82nd Scientific Session of the American-Heart-Association, 14 Nov 2009 - 18 Nov 2009. 120:S484-S485. LIPPINCOTT WILLIAMS & WILKINS (3 Nov 2009).
• Prieto-Merino D; Gupta AK; Dobson J; Chang CL; Mastorantonakis S; Sever PS; Dahlof B; Wede H; et alPocock S; Poulter NR. ASCORE: AN UP-TO-DATE CARDIOVASCULAR RISK SCORE FOR HYPERTENSIVE PATIENTS REFLECTING CONTEMPORARY CLINICAL PRACTICES DEVELOPED USING THE ASCOT TRIAL DATABASE. 19th European Meeting on Hypertension, 12 Jun 2009 - 16 Jun 2009. 27:S315-S315. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2009). Author weblink.
• Poulter NR; Chang CL; Dahlof B; Gupta AK; Sever PS; Wedel H; ASCOT Investigators. Evaluating the efficacy of the stepped-care anti-hypertensive strategies used in the Anglo-Scandinavian Cardiac Outcomes Trial BP Lowering Arm (ASCOT-BPLA). 18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension. 26:S10-S10. (Jun 2008).
• Gupta AK; Dahlof B; Dobson J; Sever PS; Wedel H; Poulter NR; Anglo-Scandinavian Cardiac Outcome. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-blood pressure lowering arm and the relative influence of antihypertensive medication. 21st Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension. 31:982-988. (May 2008).
• Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B; et alASCOT Trial Invest. An amlodipine-based regimen is cost-effective compared to an atenolol-based regimen: Results from the Anglo-Scandinavian cardiac outcomes trial. 17th European Meeting on Hypertension. 25:S137-S137. (Jun 2007).
• Gupta AK; Poulter NR; Dahlot B; Sever PS; Wedel H. Role of metabolic syndrome, independent of its components, in prediction of cardiovascular outcomes in hypertensive patients of ASCOT- BPLA. 56th Annual Scientific Session of the American-College-of-Cardiology, 24 Mar 2007 - 27 Mar 2007. 49:417A-417A. ELSEVIER SCIENCE INC (6 Mar 2007). Author weblink.
• Poulter NR; Chang CL; Sever PS; Dahlot B; Hans W. The impact of age on blood pressure reduction due to atenolol and amlodipine in the blood-pressure lowering arm of the anglo-scandinavian cardiac outcomes trial. 56th Annual Scientific Session of the American-College-of-Cardiology. 49:371A-371A. (6 Mar 2007).
• Gupta AK; Poulter NR; Dahlof B; Marro JE; Sever PS; Wedel H. Determinants of new onset diabetes among hypertensive patients randomised in the ASCOT-BPLA trial. 21sth Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension, 15 Oct 2006 - 19 Oct 2006. 24:43-43. LIPPINCOTT WILLIAMS & WILKINS (1 Dec 2006). Author weblink.
• Chang CL; Poulter NR; Chapman N; Dahlof B; Sever PS; Wedel H. The effect on blood pressure and lipid profiles of doxazosin GITS as a third-line agent in the ASCOT-BPLA trial. 21sth Scientific Meeting of the International-Society-of-Hypertension/5th Asian-Pacific Congress of Hypertension/29th Annual Scientific Meeting of the Japanese-Society-of-Hypertension, 15 Oct 2006 - 19 Oct 2006. 24:64-64. LIPPINCOTT WILLIAMS & WILKINS (1 Dec 2006). Author weblink.
• Collier DJ; Caulfield MJ; Poulter NR; Dahlof B; Wedel H; Sever PS. Did older or younger patients benefit more from amlodipine based vs atenolol based therapy in ASCOT-BPLA?. 79th Annual Scientific Session of the American-Heart-Association, 12 Nov 2006 - 15 Nov 2006. 114:896-896. LIPPINCOTT WILLIAMS & WILKINS (31 Oct 2006). Author weblink.
• Chang CL; Chapman JN; Sever PS; Dahlof B; Wedel H; Poulter NR. The effect on blood pressure and lipid profiles of doxazosin gits as a third-line antihypertensive agent in the anglo-Scandinavian cardiac outcomes trial (ASCOT). 16th European Meeting on Hypertension. 24:S3-S4. (Jun 2006).
• Poulter NR; Dahlof B; Sever PS; Wedel H; Collier D. Impact of atorvastatin on cardiovascular events in 2440 men and women aged 65 years and above: Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). International Stroke Conference. 37:695-695. (Feb 2006).
• Sever PS; Dahlof B; Poulter NR; Wedel H. Anglo-scandinavian cardiac outcomes trial: Lipid lowering arm (ASCOT LLA) revisited: Interaction of antihypertensive and lipid lowering therapy. 78th Annual Scientific Session of the American-Heart-Association. 112:U188-U188. (25 Oct 2005).
• Poulter N; Sever PS. Do statins lower blood pressure? Evidence from the anglo-scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA). 77th Scientific Meeting of the American-Heart-Association, 7 Nov 2004 - 10 Nov 2004. 110:402-402. LIPPINCOTT WILLIAMS & WILKINS (26 Oct 2004). Author weblink.
• Sever PS; Dahlof B; Poulter N; Wedel H. Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): Results in the subgroup of patients with diabetes. 54th Annual Scientific Session of the American-College-of-Cardiology, 7 Mar 2004 - 10 Mar 2004. 43:529A-529A. ELSEVIER SCIENCE INC (3 Mar 2004). Author weblink DOI.
• Sharp AS; Zambanini A; Hughes AD; Byrd S; Shields D; Fitzgerald D; Lyons S; O'Brien E; et alStanton A; Poulter N; Sever PS; Thom SAG; Mayet J. Atorvastatin does not reduce LV mass or affect diastolic function after one year of treatment. Meeting of the British Society of Echocardiography. 89:41-42. (Nov 2003).
• Ariff B; O'Neill A; Xu XY; Sever PS; Stanton AV; Hughes AD; Thom SM. Divergent effects on cardiac and carotid vascular remodelling in hypertensive subjects treated with candesartan cilexitil & atenolol. 7th Annual Meeting of the European-Council-for-Blood-Pressure-and-Cardiovascular-Research, 11 Oct 2002 - 13 Oct 2002. 40:582-582. LIPPINCOTT WILLIAMS & WILKINS (1 Oct 2002). Author weblink.
• Hassan M; Stanton AV; Mistry P; Martinez-Perez E; Parker KH; Sever PS; Thom SAM; Hughes AD. Effect of antihypertensive treatment on hypertensive changes in the human retina. 7th Annual Meeting of the European-Council-for-Blood-Pressure-and-Cardiovascular-Research, 11 Oct 2002 - 13 Oct 2002. 40:569-569. LIPPINCOTT WILLIAMS & WILKINS (1 Oct 2002). Author weblink.
• Ariff BB; Zambanini A; Sever PS; Thom SAM; Hughes AH. Determining carotid artery shear stress with ultrasound: A more realistic approach. 19th Meeting of the International-Society-for-Hypertension/12th European-Society-of-Hypertension Meeting. 20:S217-S217. (Jun 2002).
• Ariff BB; Gustavsson T; Zambanini A; Sever PS; Hughes AD; Thom SAM. Improving carotid intima-media thickness measurement: Using digital images with an existing semi-automated analysis package. 19th Meeting of the International-Society-for-Hypertension/12th European-Society-of-Hypertension Meeting, 23 Jun 2002 - 27 Jun 2002. 20:S342-S342. LIPPINCOTT WILLIAMS & WILKINS (1 Jun 2002). Author weblink.
• Clunn GF; Patel MK; Sever PS; Hughes AD. Roles of Rho-kinase and p38 mitogen activated protein kinase pathways in control of human smooth muscle cell chemotaxis and morphology. 19th Meeting of the International-Society-for-Hypertension/12th European-Society-of-Hypertension Meeting. 20:S176-S176. (Jun 2002).
• Sever PS. The heterogeneity of hypertension. Satellite Symposium on a New Fixed Low-Dose Combination - Blood Pressure Control and Beyond, at the XXIst Congress of the European-Society-of-Cardiology. 1:L10-L13. (Aug 1999).
• Sever PS; Mancia G. Clinical implications of differences between angiotensin II antagonists. European-Society-of-Cardiology Meeting on Angiotensin II Antagonists in Hypertension and Beyond, 24 Aug 1997. 4:S392-S396. AMER MED PUBLISHING, M W C COMPANY (1 Jul 1998). Author weblink.
• SCHWEIZERREISCH C; FLISER D; MANN J; RITZ E. 36 MONTHS FOLLOW-UP IN PATIENTS WITH RENAL-FAILURE ON CONVERTING ENZYME-INHIBITORS OR ALTERNATIVE ANTIHYPERTENSIVES. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 218-220. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• KVIST S; KAHR O; JUUL B; MULVANY MJ. A METHOD FOR MEASUREMENTS OF ACE ACTIVITY IN THE INTACT PREPARATION OF SMALL VESSELS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 249-251. (1991).
• SONNENBLICK H; LEJEMTEL T; ENG C; ZHAO M; HOCHMAN J; CAPASSO J; ANVERSA P. A ROLE FOR ACE INHIBITORS IN MODULATING VENTRICULAR REMODELING AND ALTERING THE COURSE OF VENTRICULAR DYSFUNCTION AND RESULTANT HEART-FAILURE IN ISCHEMIA AND MYOCARDIAL-INFARCTION. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 38-42. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• LINZ W; HENNING R; SCHOLKENS BA; BECKER RHA. ACE INHIBITION AND ANGIOTENSIN-II RECEPTOR ANTAGONISM ON DEVELOPMENT AND REGRESSION OF CARDIAC-HYPERTROPHY IN RATS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 188-190. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• ROSENFELD JB; ERMAN A; WINKLER J; CHENGAL B; RABINOV M; ZELYKOVSKI A; TADJER S; SHMUELI J; et alLEVI E. ACUTE EFFECTS OF RAMIPRIL IN MAN - INHIBITION OF SERUM AND TISSUE ANGIOTENSIN CONVERTING ENZYME. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 106-109. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• WOOD JM. ALTERNATIVE WAYS TO INHIBIT THE RENIN-ANGIOTENSIN SYSTEM - GENERAL OVERVIEW. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 110-117. (1991).
• SCOTTBURDEN T; MACKIE EJ; VANHOUTTE PM. ANGIOTENSIN AND VASCULAR STRUCTURE - MODULATION OF EXTRACELLULAR-MATRIX SYNTHESIS IN CULTURED SMOOTH-MUSCLE CELLS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 134-136. (1991).
• JANDELEIT K; JOHNSTON C; HETTIARACHCHI M; PAXTON D; PERICH R; JACKSON B. ANGIOTENSIN CONVERTING ENZYME (ACE) IN MICROVESSELS AND MACROVESSELS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 230-233. (1991).
• HUANG WC; FAN CD; WANG SL; WEI CH. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITION AND DIETARY-PROTEIN RESTRICTION DIMINISH MESANGIAL ACCUMULATION OF MACROMOLECULES IN AMINONUCLEOSIDE NEPHROSIS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 202-205. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• DEVEREUX RB. ANGIOTENSIN CONVERTING ENZYME-INHIBITION AND REGRESSION OF HYPERTENSIVE LEFT-VENTRICULAR HYPERTROPHY. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 43-52. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• GUIDI E; HOLLENBERG NK. ANGIOTENSIN-I BEHAVES DIFFERENTLY FROM ANGIOTENSIN-II IN SHR RENAL VESSELS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 237-239. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• BARNES JM; BARNES NM; COSTALL B; GE J; KELLY ME; MURPHY DA; NAYLOR RJ. ANXIOLYTIC-LIKE AND COGNITIVE ENHANCING ACTION OF THE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST, DUP 753. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 260-264. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• SIMON A; LEVENSON J; PITHOISMERLI I; MEGNIEN JL. ARTERIAL EFFECTS OF ACE INHIBITION IN HUMAN HYPERTENSION - ROLE OF PRESSURE AND FLOW-MEDIATED VASCULAR FORCES. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 30-34. (1991).
• SCHWIELER JH; NUSSBERGER J; KAHAN T; HJEMDAHL P. ARTERIOVENOUS OVERFLOW OF ANGIOTENSIN-II IN CANINE GRACILIS MUSCLE VASCULATURE INVIVO. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 152-152. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• EGGENA P; WILLSEY P; TRUCKENBROD L; JAMGOTCHIAN N; HU MS; BARRETT JD; EGGENA MP; CLEGG K; et alNAKHOUL F; LEE DBN. BLOOD-PRESSURE, TISSUE RENIN SYSTEMS AND RECOMBINANT-HUMAN-ERYTHROPOIETIN. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 148-151. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• NAFTILAN ACJ; ELDRIDGE CS; GILLILAND K. CELLULAR MECHANISM OF ANGIOTENSIN-II INDUCTION OF THE PROTOONCOGENE C-JUN. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 20-25. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• GROVER GJ; SLEPH PG; DZWONCZYK S; WANG P; FUNG W; TOBIAS D; SARGENT CA; CUSHMAN DW. COMPARISON OF CARDIOPROTECTIVE AND CARDIAC ACE INHIBITORY ACTIONS OF 7 ACE INHIBITORY DRUGS IN THE ISCHEMIC ISOLATED RAT-HEART. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 178-183. (1991).
• SINGER DRJ; MARKANDU ND; CAPPUCCIO FP; MACGREGOR GA. CONVERTING ENZYME-INHIBITION - ADDITIVE EFFECTS OF MODERATE SODIUM RESTRICTION IN ESSENTIAL-HYPERTENSION. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 168-171. (1991).
• CAPPUCCIO FP; MARKANDU ND; SINGER DRJ; MACGREGOR GA. CONVERTING ENZYME-INHIBITORS, CALCIUM-ANTAGONISTS AND THIAZIDE DIURETICS IN COMBINATION - A RATIONAL APPROACH TO THE TREATMENT OF HYPERTENSION. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 165-167. (1991).
• MCCANCE AJ; FORFAR JC. DECREASED SYMPATHETIC TONE IN PATIENTS WITH CHRONIC HEART-FAILURE TREATED WITH RAMIPRIL. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 278-281. (1991).
• CHOPRA M; SMITH W; DARGIE HJ; MCMURRAY J. DIFFERENTIAL ANTIOXIDANT ACTION OF ANGIOTENSIN CONVERTING ENZYME-INHIBITORS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 271-273. (1991).
• BATIN P; GARDINER SM; COMPTON AM; BENNETT T. DIFFERENTIAL REGIONAL HEMODYNAMIC-EFFECTS OF THE NONPEPTIDE ANGIOTENSIN-II ANTAGONIST, DUP 753, IN WATER-REPLETE AND WATER-DEPRIVED BRATTLEBORO RATS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 256-259. (1991).
• MULVANY MJ. DIRECT ACTIONS OF ANGIOTENSIN-II ON VASCULAR TONE - A BRIEF REVIEW. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 15-19. (1991).
• GRIMA M; MICHEL B; BARTHELMEBS M; IMBS JL. DISSOCIATION OF THE EFFECTS OF RAMIPRIL ON PLASMA AND RENAL BRUSH-BORDER ANGIOTENSIN CONVERTING ENZYME IN THE RAT. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 144-147. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• BORGHI C; BACCHELLI S; ESPOSTI DD; MARESTA A; AMBROSIONI E; MAGNANI B. EARLY AND LONG-TERM ACE INHIBITION IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION - A PILOT-STUDY. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 244-248. (1991).
• TIAN R; BOTTCHER M; CHRISTIANSEN EH; ANDREASEN F. EFFECT OF EARLY ACE INHIBITION ON CARDIAC-HYPERTROPHY AND PLASMA NORADRENALINE IN RATS AFTER MYOCARDIAL-INFARCTION. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 265-267. (1991).
• LEVER AF; BEATTIE E; BROWN W; FOLKOW B; GRIFFIN SA; HARRAP S; MACPHERSON F; MORTON JJ; et alMULVANY MJ. EFFECTS OF ANGIOTENSIN-II, GROWTH-FACTORS AND INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM ON ARTERIAL-PRESSURE AND CARDIOVASCULAR STRUCTURE. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 3-9. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• BOSSALLER C; GRAF K; AUCHSCHWELK W; GRAFE M; BAUMGARTEN K; SCHULER S; WARNECKE H; REGITZ V; et alFLECK E. EFFECTS OF CONVERTING ENZYME-INHIBITION ON ENDOTHELIUM-DEPENDENT RELAXATIONS AND BRADYKININ METABOLISM IN CORONARY-ARTERIES AND CULTURED ENDOTHELIAL-CELLS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 234-236. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• YEO WW; RAMSAY LE. EPIDEMIOLOGY OF COUGH WITH ENALAPRIL. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 282-285. (1991).
• VIBERTI GC; MESSENT J. FAMILIAL AND ENVIRONMENTAL-FACTORS IN THE GENESIS OF RENOVASCULAR COMPLICATIONS IN DIABETES-MELLITUS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 79-83. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• ROLLAND PH; SOUCHET T; FRIGGI A; BERENGERBAHUET FP; BODARD H; FAYE MM; GARCON D; CHARPIOT P; et alBARLATIER A; CALAF R; LAFONT H; LECHENE P; DOMINGO N; PIQUET P; TRANIER P; MERCIER C; LUCCIONI R. HISTOPATHOLOGICAL AND HEMODYNAMIC EVIDENCES OF ENALAPRIL-INDUCED REDUCTION OF VASCULAR ATHEROSCLEROTIC DISEASE IN PITMAN-MOORE MINIPIGS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 153-156. (1991).
• ELLIOTT WJ; MARTIN WB; MURPHY MB. IMPROVEMENT IN RESULTS OF SCREENING-TESTS FOR HYPERTENSION USING ACE INHIBITORS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 206-208. (1991).
• WOIE L; DICKSTEIN K; KAADA B. INCREASE IN VASOACTIVE INTESTINAL POLYPEPTIDES (VIP) BY LISINOPRIL. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 198-201. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• MOTWANI JG; STRUTHERS AD. INDOMETHACIN AUGMENTS ANGIOTENSIN II-INDUCED ANTINATRIURESIS AND RENAL VASOCONSTRICTION IN MAN. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 221-222. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• KRAMER HJ; GLANZER K; MEYERLEHNERT H; MOHAUPT M; PREDEL HG. INTERACTIONS OF ACE INHIBITORS WITH VASOACTIVE PEPTIDES. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 191-194. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• PLOTH DW; INGRAM R; MACKENZIE HS. MECHANISMS OF ACUTE-RENAL-FAILURE IN ONE KIDNEY, ONE CLIP HYPERTENSION DURING CONVERTING ENZYME-INHIBITION AND REDUCED BLOOD-PRESSURE. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 209-212. (1991).
• DAEMEN M; LOMBARDI DM; BOSMAN FT; SCHWARTZ SM. MITOGENIC EFFECTS OF ANGIOTENSIN-II ON VASCULAR SMOOTH-MUSCLE CELLS INVIVO. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 137-139. (1991).
• STONIER C; HARDING P; ABER GM. MODULATION OF GLOMERULAR PROSTANOID PRODUCTION BY ACE INHIBITORS IN NORMOTENSIVE AND SPONTANEOUSLY HYPERTENSIVE RATS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 184-187. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• HJEMDAHL P; SCHWIELER JH. MODULATION OF SYMPATHOADRENAL FUNCTION BY THE RENIN-ANGIOTENSIN SYSTEM. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 98-105. (1991).
• WEBER KT; BRILLA CG; JANICKI JS; REDDY HK; CAMPBELL SE. MYOCARDIAL FIBROSIS AND HYPERTROPHY - ROLE OF CIRCULATING ANGIOTENSIN-II AND ALDOSTERONE. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 53-59. (1991).
• KATZ RJ; LEVY WS. NITROGLYCERIN TOLERANCE IS MODIFIED BY ANGIOTENSIN CONVERTING ENZYME-INHIBITORS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 274-277. (1991).
• TIMMERMANS PBMWM; CARINI DJ; CHIU AT; DUNCIA JV; HERBLIN WF; PRICE WA; SMITH RD; WELLS GJ; et alWONG PC; WEXLER RR; JOHNSON AL. NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS - A NOVEL-APPROACH TO INHIBIT THE RENIN-ANGIOTENSIN SYSTEM. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 118-124. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• LARAGH JH. PLASMA-RENIN AS A RISK FACTOR FOR HEART-ATTACK AND STROKE IN HYPERTENSION. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 60-64. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• SAMANI NJ; KELLY MP. POSSIBLE FATES OF LOCALLY SYNTHESIZED RENIN AND ANGIOTENSINOGEN - IMPLICATIONS FOR TISSUE RENIN-ANGIOTENSIN SYSTEMS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 90-97. (1991).
• STIER CT; SIM J; MAHBOUBI K; SHEN W; LEVINE S; CHANDER PN. PREVENTION OF STROKE AND HYPERTENSIVE RENAL-DISEASE BY THE ANGIOTENSIN-II RECEPTOR ANTAGONIST DUP 753 IN SALT-LOADED STROKE-PRONE SHR. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 252-255. (1991).
• SEALEY JE. PRORENIN - A MECHANISM FOR MAINTAINING TISSUE PERFUSION IN THE PRESENCE OF CIRCULATING RENIN. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 65-70. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• FLETCHER AE; BULPITT CJ. QUALITY-OF-LIFE ON ACE INHIBITORS - A REVIEW OF THE RESULTS OF RECENT TRIALS IN HYPERTENSION. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 286-288. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• SOUBRIER F; HUBERT C; WEI L; RIGAT B; CLAUSER E; ALHENCGELAS F; CORVOL P. RECENT ADVANCES IN MOLECULAR-BIOLOGY AND BIOCHEMISTRY OF THE HUMAN ANGIOTENSIN-I CONVERTING ENZYME. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 123-131. (1991).
• DANSER AHJ; KONING MMG; SASSEN LMA; ADMIRAAL PJJ; DERKX FHM; VERDOUW PD; SCHALEKAMP M. REGIONAL PRODUCTION OF ANGIOTENSIN-I - CONTRIBUTION OF VASCULAR KIDNEY-DERVIED RENIN. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 140-143. (1991).
• DERKX FHM; DEWIND AE; LIPOVSKY MM; STROES ESG; PIETERMAN H; VANDENMEIRACKER AH; WENTING GJ; VELD A; et alSCHALEKAMP M. RENAL-VEIN RENIN LATERALIZATION IS NOT IMPROVED BY CAPTOPRIL TREATMENT. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 213-217. (1991).
• PARVING HH. RENOPROTECTIVE ACTION OF ACE INHIBITION IN DIABETES-MELLITUS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 76-78. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• JOHNSTON CI; FABRIS B; MOOSER V; JANDELEIT K. RENOPROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME-INHIBITION. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 71-75. (1991).
• WILCOX CS; WELCH WJ; FOLGER WH; SNELLEN H. RENOVASCULAR HYPERTENSION IN THE RAT - ROLES OF ANGIOTENSIN, PROSTAGLANDINS AND THROMBOXANE. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 175-177. (1991).
• SCHACHTER M. ROLE OF ANGIOTENSIN-II IN GROWTH-REGULATION IN VASCULAR SMOOTH-MUSCLE. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 10-14. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• HELLER J; KRAMER HJ; HORACEK V. ROLES OF BRADYKININ AND PROSTAGLANDINS IN THE CANINE RENAL HEMODYNAMIC-RESPONSES TO ACE INHIBITION. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 195-197. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• VANKRIMPEN C; CLEUTJENS JPM; SCHOEMAKER RG; DAEMEN M; SMITS JFM. STRUCTURAL AND FUNCTIONAL-EFFECTS OF ANGIOTENSIN-II RECEPTOR BLOCKADE AFTER MYOCARDIAL-INFARCTION IN THE RAT. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 240-243. (1991).
• TSUNODA M; NAKAJIMA H; KAWAMURA A; OHOKA M; YAMASAKI K; WATANABE K. SUDDEN-DEATH IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 268-270. (1991).
• ROCCO S; OPOCHER G; FALLO F; CARPENE G; MANTERO F. THE CAPTOPRIL TEST IN THE DIFFERENTIAL-DIAGNOSIS OF PRIMARY ALDOSTERONISM. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 223-225. (1991).
• SALVETTI A; CAIAZZA A; GHISONI F; CARDELLINO G; MILLOZ N; CIRCO A; GULIZIA M; SABA P; et alGIUNTOLI F; SABA G; BRANCADORO R. THE DOSE-RESPONSE CURVE OF LISINOPRIL IN ESSENTIAL HYPERTENSIVES - A CROSS-OVER MULTICENTER STUDY. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 161-164. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• ISLIM IF; BEEVERS DG; BAREFORD D. THE EFFECT OF ANGIOTENSIN CONVERTING ENZYME-INHIBITORS ON PLATELET ACTIVITY IN ESSENTIAL-HYPERTENSION. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 172-174. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• SHAHI M; THOM S; POULTER N; SEVER PS; FOALE RA. THE TIME COURSE AND DETERMINANTS OF REGRESSION OF LEFT-VENTRICULAR HYPERTROPHY. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 157-160. (1991).
• UNGER T; GOHLKE P; PAUL M; RETTIG R. TISSUE RENIN-ANGIOTENSIN SYSTEMS - FACT OR FICTION. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 84-89. (1991).
• STRUYKERBOUDIER HAJ; MESSING MWJ; NELISSEN H; HUIJBERTS MSP; LENOBLE FAC; SMITS JFM. VASCULAR ACTIONS OF ACE INHIBITORS IN HYPERTENSION - STRUCTURAL AND FUNCTIONAL CONSEQUENCES. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION. 26-29. (1991).
• DOHI Y; HAHN AWA; BOULANGER CM; LUSCHER TF. VASCULAR RENIN-ANGIOTENSIN SYSTEM AND ENDOTHELIAL FUNCTION - EFFECT OF ACE INHIBITORS. 2ND INTERNATIONAL SYMP ON CURRENT ADVANCES IN ANGIOTENSIN CONVERTING ENZYME INHIBITION, 17 Feb 1991 - 21 Feb 1991. 226-229. CHURCHILL LIVINGSTONE LTD (1 Jan 1991). Author weblink.
• SCHACHTER M; GALLAGHER KL; SEVER PS. INTRACELLULAR FREE MAGNESIUM IN A VASCULAR SMOOTH-MUSCLE CELL-LINE. COLLOQUIUM AT THE 635TH MEETING OF THE BIOCHEMICAL SOC : LIPIDS, LIPOPROTEINS AND ANTIOXIDANTS IN CARDIOVASCULAR DYSFUNCTION, Jul 1990. 18:1266-1266. PORTLAND PRESS (1 Dec 1990). Author weblink.
• MENARD J; MICHEL JB. ARE ACE INHIBITORS THE 1ST CHOICE FOR 1ST-STEP THERAPY IN HYPERTENSION. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR. 166:3-13. (1990).
• BELLET M; FRIEDRICHS D; BODIN F; TANNER K. BENAZEPRIL - CLINICAL-RESPONSE COMPARED WITH OTHER ACE INHIBITORS. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR. 166:99-109. (1990).
• DEQUATTRO V. BENAZEPRIL COMPARED WITH OTHER ANTIHYPERTENSIVE AGENTS, SINGLY AND IN COMBINATION - A REVIEW. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR. 166:91-98. (1990).
• DESSIFULGHERI P; MOTOLESE M; DINOTO G; DELFINO D; GIACCHETTI G; BORIA C; PACI MV; RAPPELLI A. BENAZEPRIL EFFECTS ON ATRIAL-NATRIURETIC-FACTOR. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:143-151. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• GOMEZ HJ; GLAZER R; MALLOWS S; DESILVA J. BENAZEPRIL IN THE TREATMENT OF OLDER AND ELDERLY HYPERTENSIVE PATIENTS. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:111-121. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• KAISER G. BENAZEPRIL PHARMACOKINETIC PROFILE IN SPECIFIC SUBPOPULATIONS. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:29-39. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• SLEIGHT P. BLOOD-PRESSURE MEASUREMENT FOR PARTICULAR PURPOSES - STRENGTHS AND WEAKNESSES OF CERTAIN TECHNIQUES. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:77-83. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• POOL JL; GOMEZ HJ; TAYLOR AA. DOSE-RESPONSE RELATIONSHIP OF BENAZEPRIL ONCE DAILY IN MILD-TO-MODERATE HYPERTENSION. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:41-50. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• CLOSE P; ROUSSEAU M; GURNE O; BENEDICT CR; POULEUR H. EFFECTS OF BENAZEPRILAT ON LEFT-VENTRICULAR SYSTOLIC AND DIASTOLIC FUNCTION AND NEUROHUMORAL STATUS IN PATIENTS WITH CORONARY-ARTERY DISEASE. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR. 166:153-159. (1990).
• LEVENS NR. FUTURE BLOCKERS OF THE RENIN-ANGIOTENSIN SYSTEM. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:169-181. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• CHEN B; PERICH R; JACKSON B; PAXTON D; PUPIC V; FABRIS B; JOHNSTON CI. INHIBITION OF TISSUE ACE BY BENAZEPRIL. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:17-27. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• OLDENBROEK C. INVASIVE 24-HOUR BLOOD-PRESSURE MONITORING IN CONTROLLED TRIAL OF BENAZEPRIL. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:67-75. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• SEVER PS. LOOKING AHEAD. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:183-184. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• PESSINA AC; MORMINO P; PALATINI P; VALLE F; DELTORRE M; MOS L; VAROTTO L; GIULIANO G; et alCASIGLIA E; DALPALU C. MORNING OR EVENING BENAZEPRIL ADMINISTRATION IN HYPERTENSION - A RANDOMIZED STUDY USING INTRAARTERIAL BLOOD-PRESSURE MONITORING. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:51-57. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• BOLLI GB; TORLONE E; DEFEO P; FANELLI C; PERRIELLO G; MOTOLESE M; BRUNETTI P. RATIONALE FOR ACE INHIBITION IN HYPERTENSION ASSOCIATED WITH DIABETES-MELLITUS. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:123-130. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• MASCHIO G; VALVO E; BEDOGNA V; ALBERTI D. RENAL ASPECTS OF BENAZEPRIL TREATMENT IN ESSENTIAL-HYPERTENSION AND KIDNEY-DISEASE. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR. 166:131-141. (1990).
• NUSSBERGER J. RESETTING OF THE RENIN-ANGIOTENSIN SYSTEM AFTER CONVERTING ENZYME-INHIBITION WITH BENAZEPRIL. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:15-16. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• PETHICA BD. SAFETY AND TOLERABILITY OF BENAZEPRIL IN THE TREATMENT OF HYPERTENSION - AN OVERVIEW. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR, 11 Jan 1990 - 14 Jan 1990. 166:161-167. ROYAL SOC MEDICINE SERVICES LTD (1 Jan 1990). Author weblink.
• AGABITIROSEI E; RIZZONI D; ZULLI R; MUIESAN L; MOTOLESE M; MUIESAN G. SUSTAINED ANTIHYPERTENSIVE EFFECTS OF BENAZEPRIL DEMONSTRATED BY AMBULATORY MONITORING - PLACEBO-CONTROLLED TRIAL AT 2 DOSAGE LEVELS. SYMP ON BENAZEPRIL : PROFILE OF A NEW ACE INHIBITOR. 166:59-66. (1990).